Cyclopropyl MIDA Boronate

ABSTRACT

This disclosure concerns a protected cyclopropylboronic acid comprising a substituted cyclopropyl group and a boronic ester group having a protecting group. The protecting group is an N-methyliminodiacetic acid (MIDA) group or MIDA-based group.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of the earlier filing date under 35U.S.C. §119(e) of pending U.S. application 61/418,654, filed Dec. 1,2010, which is hereby incorporated herein by reference in its entirety.

BACKGROUND

The cyclopropyl group is a popular motif for exploringstructure-activity relationships in medicinal chemistry. However,substituted cyclopropyl groups have been less frequently employed, inpart due to their more complicated installation. Certain methods tointroduce cyclopropyl groups can be found in Tetrahedron Letters 51(2010) 1009-1011. However, there are still a limited number of methodsto prepare such compounds, particularly with stereocontrol.

SUMMARY

This disclosure concerns a protected cyclopropylboronic acid comprisinga substituted cyclopropyl group and a boronic ester group having aprotecting group. The protecting group is an N-methyliminodiacetic acid(MIDA) group or MIDA-based group.

The protected cyclopropylboronic acid can undergo deprotection undermild conditions with high yields. Such a system can control thereactivity of boronic acids and expand the versatility of organoboronicacids in transition metal catalyzed reactions, such as palladiumcatalyzed cross-coupling reactions, for example, the Suzuki reaction orof other reactions of boronic acids. Thus, the protectedcyclopropylboronic acid can deliver a substituted cyclopropyl group in acoupling reaction with improved selectivity compared to a correspondingreaction without use of the protected cyclopropylboronic acid.

One embodiment provides a protected organoboronic acid of the formula I:

R¹ is selected from hydrogen, alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, aryl, and heteroaryl;and

R^(2a), R^(2b), R^(2c), and R^(2d) are independently selected fromhydrogen, alkyl, substituted alkyl, halogen, hydroxyl, cyano, phosphate,alkoxy, substituted alkoxy, carboxyl, carboxyl ester, aryl, substitutedaryl, heteroaryl, substituted heteroaryl, heterocyclyl, substitutedheterocyclyl, alkenyl, substituted alkenyl, amino, substituted amino,acyl, acylamino, aminoacyl, alkoxycarbonylamino, thiol, alkylthiol,substituted thioalkoxy, and sulfonyl,

wherein at least one of R^(2a), R^(2b), R^(2c), and R^(2d) is nothydrogen.

Also provided are methods of preparing the protected cyclopropylboronicacids and method of using the protected cyclopropylboronic acids inchemical reactions. Further provided are methods and reagents forinstallation of a substituted cyclopropyl group with stereochemicalcontrol.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the structure oftrans-2-(trifluoromethyl)cyclopropylboronic acid MIDA ester from X-raycrystallography studies.

DETAILED DESCRIPTION

This disclosure concerns a protected cyclopropylboronic acid comprisinga substituted cyclopropyl group and a boronic ester group having a MIDAor MIDA-based protecting group.

Before the present invention is further described, it is to beunderstood that this invention is not limited to particular embodimentsdescribed, as such may, of course, vary. It is also to be understoodthat the terminology used herein is for the purpose of describingparticular embodiments only, and is not intended to be limiting, sincethe scope of the present invention will be limited only by the appendedclaims.

It must be noted that as used herein and in the appended claims, thesingular forms “a,” “an,” and “the” include plural referents unless thecontext clearly dictates otherwise. It is further noted that the claimsmay be drafted to exclude any optional element. As such, this statementis intended to serve as antecedent basis for use of such exclusiveterminology as “solely,” “only” and the like in connection with therecitation of claim elements, or use of a “negative” limitation.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range and any other stated or intervening value in thatstated range, is specifically contemplated. The upper and lower limitsof these smaller ranges may independently be included in the smallerranges, and are also encompassed within the invention, subject to anyspecifically excluded limit in the stated range. Where the stated rangeincludes one or both of the limits, ranges excluding either or both ofthose included limits are also included in the invention.

The publications discussed herein are provided solely for theirdisclosure prior to the filing date of the present application. Nothingherein is to be construed as an admission that the present invention isnot entitled to antedate such publication by virtue of prior invention.Further, the dates of publication provided may be different from theactual publication dates which may need to be independently confirmed.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can also beused in the practice or testing of the present invention, the preferredmethods and materials are now described. All publications mentionedherein are incorporated herein by reference to disclose and describe themethods and/or materials in connection with which the publications arecited.

Except as otherwise noted, the methods and techniques of the presentembodiments are generally performed according to conventional methodswell known in the art and as described in various general and morespecific references that are cited and discussed throughout the presentspecification. See, e.g., Loudon, Organic Chemistry, Fourth Edition, NewYork: Oxford University Press, 2002, pp. 360-361, 1084-1085; Smith andMarch, March's Advanced Organic Chemistry: Reactions, Mechanisms, andStructure, Fifth Edition, Wiley-Interscience, 2001; or Vogel, A Textbookof Practical Organic Chemistry, Including Qualitative Organic Analysis,Fourth Edition, New York: Longman, 1978.

The nomenclature used herein to name the subject compounds isillustrated in the Examples herein. This nomenclature has generally beenderived using the commercially-available AutoNom software (MDL, SanLeandro, Calif.).

TERMS

The following terms have the following meanings unless otherwiseindicated. Any undefined terms have their art recognized meanings.

“Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groupshaving from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms.This term includes, by way of example, linear and branched hydrocarbylgroups such as methyl (CH₃—), ethyl (CH₃CH₂—), n-propyl (CH₃CH₂CH₂—),isopropyl ((CH₃)₂CH—), n-butyl (CH₃CH₂CH₂CH₂—), isobutyl ((CH₃)₂CHCH₂—),sec-butyl ((CH₃)(CH₃CH₂)CH—), t-butyl ((CH₃)₃C—), n-pentyl(CH₃CH₂CH₂CH₂CH₂—), and neopentyl ((CH₃)₃CCH₂—).

The term “substituted alkyl” refers to an alkyl group as defined hereinwherein one or more carbon atoms in the alkyl chain have been optionallyreplaced with a heteroatom such as —O—, —N—, —S—, —S(O)_(n)— (where n is0 to 2), —NR— (where R is hydrogen or alkyl) and having from 1 to 5substituents selected from the group consisting of alkoxy, substitutedalkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl,carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy,thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-aryl,—SO₂-heteroaryl, and —NR^(a)R^(b), wherein R′ and R″ may be the same ordifferent and are chosen from hydrogen, optionally substituted alkyl,cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl andheterocyclic.

“Alkylene” refers to divalent aliphatic hydrocarbyl groups preferablyhaving from 1 to 6 and more preferably 1 to 3 carbon atoms that areeither straight-chained or branched, and which are optionallyinterrupted with one or more groups selected from —O—, —NR¹⁰—,—NR¹⁰C(O)—, —C(O)NR¹⁰— and the like. This term includes, by way ofexample, methylene (—CH₂—), ethylene (—CH₂CH₂—), n-propylene(—CH₂CH₂CH₂—), iso-propylene (—CH₂CH(CH₃)—), (—C(CH₃)₂CH₂CH₂—),(—C(CH₃)₂CH₂C(O)—), (—C(CH₃)₂CH₂C(O)NH—), (—CH(CH₃)CH₂—), and the like.

“Substituted alkylene” refers to an alkylene group having from 1 to 3hydrogens replaced with substituents as described for carbons in thedefinition of “substituted” below.

The term “alkane” refers to alkyl group and alkylene group, as definedherein.

The term “alkylaminoalkyl”, “alkylaminoalkenyl” and “alkylaminoalkynyl”refers to the groups R′NHR″— where R is alkyl group as defined hereinand R″ is alkylene, alkenylene or alkynylene group as defined herein.

The term “alkaryl” or “aralkyl” refers to the groups -alkylene-aryl and-substituted alkylene-aryl where alkylene, substituted alkylene and arylare defined herein.

“Alkoxy” refers to the group —O-alkyl, wherein alkyl is as definedherein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy,isopropoxy, n-butoxy, t-butoxy, sec-butoxy, n-pentoxy, and the like. Theterm “alkoxy” also refers to the groups alkenyl-O—, cycloalkyl-O—,cycloalkenyl-O—, and alkynyl-O—, where alkenyl, cycloalkyl,cycloalkenyl, and alkynyl are as defined herein.

The term “substituted alkoxy” refers to the groups substituted alkyl-O—,substituted alkenyl-O—, substituted cycloalkyl-O—, substitutedcycloalkenyl-O—, and substituted alkynyl-O— where substituted alkyl,substituted alkenyl, substituted cycloalkyl, substituted cycloalkenyland substituted alkynyl are as defined herein.

The term “alkoxyamino” refers to the group —NH-alkoxy, wherein alkoxy isdefined herein.

The term “haloalkoxy” refers to the groups alkyl-O— wherein one or morehydrogen atoms on the alkyl group have been substituted with a halogroup and include, by way of examples, groups such as trifluoromethoxy,and the like.

The term “haloalkyl” refers to a substituted alkyl group as describedabove, wherein one or more hydrogen atoms on the alkyl group have beensubstituted with a halo group. Examples of such groups include, withoutlimitation, fluoroalkyl groups, such as trifluoromethyl, difluoromethyl,trifluoroethyl and the like.

The term “alkylalkoxy” refers to the groups -alkylene-O-alkyl,alkylene-O-substituted alkyl, substituted alkylene-O-alkyl, andsubstituted alkylene-O-substituted alkyl wherein alkyl, substitutedalkyl, alkylene and substituted alkylene are as defined herein.

The term “alkylthioalkoxy” refers to the group -alkylene-S-alkyl,alkylene-S-substituted alkyl, substituted alkylene-S-alkyl andsubstituted alkylene-S-substituted alkyl wherein alkyl, substitutedalkyl, alkylene and substituted alkylene are as defined herein.

“Alkenyl” refers to straight chain or branched hydrocarbyl groups havingfrom 2 to 6 carbon atoms and preferably 2 to 4 carbon atoms and havingat least 1 and preferably from 1 to 2 sites of double bond unsaturation.This term includes, by way of example, bi-vinyl, allyl, andbut-3-en-1-yl. Included within this term are the cis and trans isomersor mixtures of these isomers.

The term “substituted alkenyl” refers to an alkenyl group as definedherein having from 1 to 5 substituents, or from 1 to 3 substituents,selected from alkoxy, substituted alkoxy, cycloalkyl, substitutedcycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino,acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl,carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy,thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl,—SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl.

“Alkynyl” refers to straight or branched monovalent hydrocarbyl groupshaving from 2 to 6 carbon atoms and preferably 2 to 3 carbon atoms andhaving at least 1 and preferably from 1 to 2 sites of triple bondunsaturation. Examples of such alkynyl groups include acetylenyl(—C≡CH), and propargyl (—CH₂C≡CH).

The term “substituted alkynyl” refers to an alkynyl group as definedherein having from 1 to 5 substituents, or from 1 to 3 substituents,selected from alkoxy, substituted alkoxy, cycloalkyl, substitutedcycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino,acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl,carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy,thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl,—SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl, and —SO₂-heteroaryl.

“Alkynyloxy” refers to the group —O-alkynyl, wherein alkynyl is asdefined herein. Alkynyloxy includes, by way of example, ethynyloxy,propynyloxy, and the like.

“Acyl” refers to the groups H—C(O)—, alkyl-C(O)—, substitutedalkyl-C(O)—, alkenyl-C(O)—, substituted alkenyl-C(O)—, alkynyl-C(O)—,substituted alkynyl-C(O)—, cycloalkyl-C(O)—, substitutedcycloalkyl-C(O)—, cycloalkenyl-C(O)—, substituted cycloalkenyl-C(O)—,aryl-C(O)—, substituted aryl-C(O)—, heteroaryl-C(O)—, substitutedheteroaryl-C(O)—, heterocyclyl-C(O)—, and substitutedheterocyclyl-C(O)—, wherein alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl,substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic are as defined herein. For example, acylincludes the “acetyl” group CH₃C(O)—

“Acylamino” refers to the groups —NR²⁰C(O)alkyl, —NR²⁰C(O) substitutedalkyl, N R²⁰C(O)cycloalkyl, —NR²⁰C(O) substituted cycloalkyl,—NR²⁰C(O)cycloalkenyl, —NR²⁰C(O) substituted cycloalkenyl,—NR²⁰C(O)alkenyl, —NR²⁰C(O) substituted alkenyl, —NR²⁰C(O)alkynyl,—NR²⁰C(O) substituted alkynyl, —NR²⁰C(O)aryl, —NR²⁰C(O) substitutedaryl, —NR²⁰C(O)heteroaryl, —NR²⁰C(O) substituted heteroaryl,—NR²⁰C(O)heterocyclic, and —NR²⁰C(O) substituted heterocyclic, whereinR²⁰ is hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl,substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic are as defined herein.

“Aminocarbonyl” or the term “aminoacyl” refers to the group—C(O)NR²¹R²², wherein R²¹ and R²² independently are selected from thegroup consisting of hydrogen, alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, aryl, substitutedaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic and where R²¹ and R²² are optionally joinedtogether with the nitrogen bound thereto to form a heterocyclic orsubstituted heterocyclic group, and wherein alkyl, substituted alkyl,alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl,substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic are as defined herein.

The term “alkoxycarbonylamino” refers to the group —NRC(O)OR where eachR is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl,or heterocyclyl wherein alkyl, substituted alkyl, aryl, heteroaryl, andheterocyclyl are as defined herein.

The term “acyloxy” refers to the groups alkyl-C(O)O—, substitutedalkyl-C(O)O—, cycloalkyl-C(O)O—, substituted cycloalkyl-C(O)O—,aryl-C(O)O—, heteroaryl-C(O)O—, and heterocyclyl-C(O)O— wherein alkyl,substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl,and heterocyclyl are as defined herein.

“Aminosulfonyl” refers to the group —SO₂NR²¹R²², wherein R²¹ and R²²independently are selected from the group consisting of hydrogen, alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substitutedalkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl,cycloalkenyl, substituted cycloalkenyl, heteroaryl, substitutedheteroaryl, heterocyclic, substituted heterocyclic and where R²¹ and R²²are optionally joined together with the nitrogen bound thereto to form aheterocyclic or substituted heterocyclic group and alkyl, substitutedalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic and substituted heterocyclic are as definedherein.

“Sulfonylamino” refers to the group —NR²¹SO₂R²², wherein R²¹ and R²²independently are selected from the group consisting of hydrogen, alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substitutedalkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl,cycloalkenyl, substituted cycloalkenyl, heteroaryl, substitutedheteroaryl, heterocyclic, and substituted heterocyclic and where R²¹ andR²² are optionally joined together with the atoms bound thereto to forma heterocyclic or substituted heterocyclic group, and wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substitutedalkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic, and substituted heterocyclic are as definedherein.

“Aryl” or “Ar” refers to a monovalent aromatic carbocyclic group of from6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiplecondensed rings (e.g., naphthyl or anthryl) which condensed rings may ormay not be aromatic, provided that the point of attachment is through anatom of the aromatic aryl group. This term includes, by way of example,phenyl and naphthyl. Unless otherwise constrained by the definition forthe aryl substituent, such aryl groups can optionally be substitutedwith from 1 to 5 substituents, or from 1 to 3 substituents, selectedfrom acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl,cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy,substituted alkenyl, substituted alkynyl, substituted cycloalkyl,substituted cycloalkenyl, amino, substituted amino, aminoacyl,acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl,cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl,heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substitutedthioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl, —SO-substitutedalkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-substituted alkyl,—SO₂-aryl, —SO₂-heteroaryl and trihalomethyl.

“Aryloxy” refers to the group —O-aryl, wherein aryl is as definedherein, including, by way of example, phenoxy, naphthoxy, and the like,including optionally substituted aryl groups as also defined herein.

“Amino” refers to the group —NH₂.

The term “substituted amino” refers to the group —NRR where each R isindependently selected from the group consisting of hydrogen, alkyl,substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl,substituted alkynyl, aryl, heteroaryl, and heterocyclyl provided that atleast one R is not hydrogen.

The term “azido” refers to the group —N₃.

The term “hydrazino” refers to R¹R²N—NR³R⁴ wherein R¹, R², R³, and R⁴are each independently hydrogen, alkyl, aryl, heteroaryl, or acyl.

“Carboxyl,” “carboxy” or “carboxylate” refers to —CO₂H or salts thereof.

“Carboxyl ester” or “carboxy ester” or the terms “carboxyalkyl” or“carboxylalkyl” refers to the groups —C(O)O-alkyl, —C(O)O-substitutedalkyl, —C(O)O-alkenyl, —C(O)O-substituted alkenyl, —C(O)O-alkynyl,—C(O)O-substituted alkynyl, —C(O)O-aryl, —C(O)O-substituted aryl,—C(O)O-cycloalkyl, —C(O)O-substituted cycloalkyl, —C(O)O-cycloalkenyl,—C(O)O-substituted cycloalkenyl, —C(O)O-heteroaryl, —C(O)O-substitutedheteroaryl, —C(O)O-heterocyclic, and —C(O)O-substituted heterocyclic,wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl,substituted cycloalkenyl, aryl, substituted aryl, heteroaryl,substituted heteroaryl, heterocyclic, and substituted heterocyclic areas defined herein.

“(Carboxyl ester)oxy” or “carbonate” refers to the groups—O—C(O)O-alkyl, —O—C(O)O-substituted alkyl, —O—C(O)O-alkenyl,—O—C(O)O-substituted alkenyl, —O—C(O)O-alkynyl, —O—C(O)O-substitutedalkynyl, —O—C(O)O-aryl, —O—C(O)O-substituted aryl, —O—C(O)O-cycloalkyl,—O—C(O)O-substituted cycloalkyl, —O—C(O)O-cycloalkenyl,—O—C(O)O-substituted cycloalkenyl, —O—C(O)O-heteroaryl,—O—C(O)O-substituted heteroaryl, —O—C(O)O-heterocyclic, and—O—C(O)O-substituted heterocyclic, wherein alkyl, substituted alkyl,alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl,substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, andsubstituted heterocyclic are as defined herein.

“Cyano” or “nitrile” refers to the group —CN.

“Cycloalkyl” refers to cyclic alkyl groups of from 3 to 10 carbon atomshaving single or multiple cyclic rings including fused, bridged, andspiro ring systems. Examples of suitable cycloalkyl groups include, forinstance, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyland the like. Such cycloalkyl groups include, by way of example, singlering structures such as cyclopropyl, cyclobutyl, cyclopentyl,cyclooctyl, and the like, or multiple ring structures such asadamantanyl, and the like.

The term “substituted cycloalkyl” refers to cycloalkyl groups havingfrom 1 to 5 substituents, or from 1 to 3 substituents, selected fromalkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl,acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl,carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy,thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl,—SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl.

“Cycloalkenyl” refers to non-aromatic cyclic alkyl groups of from 3 to10 carbon atoms having single or multiple rings and having at least onedouble bond and preferably from 1 to 2 double bonds.

The term “substituted cycloalkenyl” refers to cycloalkenyl groups havingfrom 1 to 5 substituents, or from 1 to 3 substituents, selected fromalkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl,cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino,substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano,halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy,thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substitutedthioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl,heterocyclooxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl,—SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl,—SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl.

“Cycloalkynyl” refers to non-aromatic cycloalkyl groups of from 5 to 10carbon atoms having single or multiple rings and having at least onetriple bond.

“Cycloalkoxy” refers to —O-cycloalkyl.

“Cycloalkenyloxy” refers to —O-cycloalkenyl.

“Halo” or “halogen” refers to fluoro, chloro, bromo, and iodo.

“Hydroxy” or “hydroxyl” refers to the group —OH.

“Heteroaryl” refers to an aromatic group of from 1 to 10 carbon atomsand 1 to 4 heteroatoms selected from the group consisting of oxygen,nitrogen, and sulfur within the ring. Such heteroaryl groups can have asingle ring (e.g., pyridinyl, imidazolyl or furyl) or multiple condensedrings (e.g., indolizinyl, quinolinyl, benzimidazolyl or benzothienyl),wherein the condensed rings may or may not be aromatic and/or contain aheteroatom, provided that the point of attachment is through an atom ofthe aromatic heteroaryl group. In certain embodiments, the nitrogenand/or sulfur ring atom(s) of the heteroaryl group are optionallyoxidized to provide for the N-oxide (N→O), sulfinyl, or sulfonylmoieties. This term includes, by way of example, pyridinyl, pyrrolyl,indolyl, thiophenyl, and furanyl. Unless otherwise constrained by thedefinition for the heteroaryl substituent, such heteroaryl groups can beoptionally substituted with 1 to 5 substituents, or from 1 to 3substituents, selected from acyloxy, hydroxy, thiol, acyl, alkyl,alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl,substituted alkoxy, substituted alkenyl, substituted alkynyl,substituted cycloalkyl, substituted cycloalkenyl, amino, substitutedamino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl,carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy,heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy,substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl,—SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl,—SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl, andtrihalomethyl.

The term “heteroaralkyl” refers to the groups -alkylene-heteroaryl wherealkylene and heteroaryl are defined herein. This term includes, by wayof example, pyridylmethyl, pyridylethyl, indolylmethyl, and the like.

“Heteroaryloxy” refers to —O-heteroaryl.

“Heterocycle,” “heterocyclic,” “heterocycloalkyl,” and “heterocyclyl”refer to a saturated or unsaturated group having a single ring ormultiple condensed rings, including fused bridged and spiro ringsystems, and having from 3 to 15 ring atoms, including 1 to 4 heteroatoms. These ring atoms are selected from the group consisting ofnitrogen, sulfur, or oxygen, wherein, in fused ring systems, one or moreof the rings can be cycloalkyl, aryl, or heteroaryl, provided that thepoint of attachment is through the non-aromatic ring. In certainembodiments, the nitrogen and/or sulfur atom(s) of the heterocyclicgroup are optionally oxidized to provide for the N-oxide, —S(O)—, or—SO₂— moieties.

Examples of heterocycles and heteroaryls include, but are not limitedto, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine,pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole,indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine,naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine,carbazole, carboline, phenanthridine, acridine, phenanthroline,isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine,imidazolidine, imidazoline, piperidine, piperazine, indoline,phthalimide, 1,2,3,4-tetrahydroisoquinoline,4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene,benzo[b]thiophene, morpholinyl, thiomorpholinyl (also referred to asthiamorpholinyl), 1,1-dioxothiomorpholinyl, piperidinyl, pyrrolidine,tetrahydrofuranyl, and the like.

Unless otherwise constrained by the definition for the heterocyclicsubstituent, such heterocyclic groups can be optionally substituted with1 to 5, or from 1 to 3 substituents, selected from alkoxy, substitutedalkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino,aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl,oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy,thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl,aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy,hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-substituted alkyl,—SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl,—SO₂-heteroaryl, and fused heterocycle.

“Heterocyclyloxy” refers to the group —O-heterocyclyl.

The term “heterocyclylthio” refers to the group heterocyclic-S—.

The term “heterocyclene” refers to the diradical group formed from aheterocycle, as defined herein.

The term “hydroxyamino” refers to the group —NHOH.

“Nitro” refers to the group —NO₂.

“Oxo” refers to the atom (═O).

“Sulfonyl” refers to the group SO₂-alkyl, SO₂-substituted alkyl,SO₂-alkenyl, SO₂-substituted alkenyl, SO₂-cycloalkyl, SO₂-substitutedcylcoalkyl, SO₂-cycloalkenyl, SO₂-substituted cylcoalkenyl, SO₂-aryl,SO₂-substituted aryl, SO₂-heteroaryl, SO₂-substituted heteroaryl,SO₂-heterocyclic, and SO₂-substituted heterocyclic, wherein alkyl,substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substitutedalkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl, heterocyclic, and substituted heterocyclic are as definedherein. Sulfonyl includes, by way of example, methyl-SO₂—, phenyl-SO₂—,and 4-methylphenyl-SO₂—.

“Sulfonyloxy” refers to the group —OSO₂-alkyl, OSO₂-substituted alkyl,OSO₂-alkenyl, OSO₂-substituted alkenyl, OSO₂-cycloalkyl,OSO₂-substituted cylcoalkyl, OSO₂-cycloalkenyl, OSO₂-substitutedcylcoalkenyl, OSO₂-aryl, OSO₂-substituted aryl, OSO₂-heteroaryl,OSO₂-substituted heteroaryl, OSO₂-heterocyclic, and OSO₂ substitutedheterocyclic, wherein alkyl, substituted alkyl, alkenyl, substitutedalkenyl, alkynyl, substituted alkynyl, cycloalkyl, substitutedcycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substitutedaryl, heteroaryl, substituted heteroaryl, heterocyclic, and substitutedheterocyclic are as defined herein.

The term “aminocarbonyloxy” refers to the group —OC(O)NRR where each Ris independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl,or heterocyclic wherein alkyl, substituted alkyl, aryl, heteroaryl andheterocyclic are as defined herein.

“Thiol” refers to the group —SH.

“Thioxo” or the term “thioketo” refers to the atom (═S).

“Alkylthio” or the term “thioalkoxy” refers to the group —S-alkyl,wherein alkyl is as defined herein. In certain embodiments, sulfur maybe oxidized to —S(O)—. The sulfoxide may exist as one or morestereoisomers.

The term “substituted thioalkoxy” refers to the group —S-substitutedalkyl.

The term “thioaryloxy” refers to the group aryl-S— wherein the arylgroup is as defined herein including optionally substituted aryl groupsalso defined herein.

The term “thioheteroaryloxy” refers to the group heteroaryl-S— whereinthe heteroaryl group is as defined herein including optionallysubstituted aryl groups as also defined herein.

The term “thioheterocyclooxy” refers to the group heterocyclyl-S—wherein the heterocyclyl group is as defined herein including optionallysubstituted heterocyclyl groups as also defined herein.

In addition to the disclosure herein, the term “substituted,” when usedto modify a specified group or radical, can also mean that one or morehydrogen atoms of the specified group or radical are each, independentlyof one another, replaced with the same or different substituent groupsas defined below.

In addition to the groups disclosed with respect to the individual termsherein, substituent groups for substituting for one or more hydrogens(any two hydrogens on a single carbon can be replaced with ═O, ═NR⁷⁰,═N—OR⁷⁰, ═N₂ or ═S) on saturated carbon atoms in the specified group orradical are, unless otherwise specified, —R⁶⁰, halo, ═O, —OR⁷⁰, —SR⁷⁰,NR⁸⁰R⁸⁰, trihalomethyl, —CN, —OCN, —SCN, —NO, —NO₂, ═N₂, —N₃, —SO₂R⁷⁰,—SO₂O⁻M⁺, —SO₂OR⁷⁰, —OSO₂R⁷⁰, —OSO₂O⁻M⁺, —OSO₂OR⁷⁰, —P(O)(O⁻)₂(M⁺)₂,—P(O)(OR⁷⁰)O⁻M⁺, —P(O)(OR⁷⁰)₂, —C(O)R⁷⁰, —C(S)R⁷⁰, —C(NR⁷⁰)R⁷⁰,—C(O)O⁻M⁺, —C(O)OR⁷⁰, —C(S)OR⁷⁰, —C(O)NR⁸⁰R⁸⁰, —C(NR⁷⁰)NR⁸⁰R⁸⁰,—OC(O)R⁷⁰, —OC(S)R⁷⁰, —OC(O)O⁻M⁺, —OC(O)OR⁷⁰, —OC(S)OR⁷⁰, —NR⁷⁰C(O)R⁷⁰,—NR⁷⁰C(S)R⁷⁰, —NR⁷⁰CO₂ ⁻M⁺, —NR⁷⁰CO₂R⁷⁰, —NR⁷⁰C(S)OR⁷⁰,—NR⁷⁰C(O)NR⁸⁰R⁸⁰, —NR⁷⁰C(NR⁷⁰)R⁷⁰ and —NR⁷⁰C(NR⁷⁰)NR⁸⁰R⁸⁰, where R⁶⁰ isselected from the group consisting of optionally substituted alkyl,cycloalkyl, heteroalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl,arylalkyl, heteroaryl and heteroarylalkyl, each R⁷⁰ is independentlyhydrogen or R⁶⁰; each R⁸⁰ is independently R⁷⁰ or alternatively, twoR⁸⁰'s, taken together with the nitrogen atom to which they are bonded,form a 5-, 6- or 7-membered heterocycloalkyl which may optionallyinclude from 1 to 4 of the same or different additional heteroatomsselected from the group consisting of O, N and S, of which N may have —Hor C₁-C₃ alkyl substitution; and each M⁺ is a counter ion with a netsingle positive charge. Each M⁺ may independently be, for example, analkali ion, such as K⁺, Na⁺, Li⁺; an ammonium ion, such as ⁺N(R⁶⁰)₄; oran alkaline earth ion, such as [Ca²⁺]_(0.5), [Mg²⁺]_(0.5), or[Ba²⁺]_(0.5) (“subscript 0.5 means e.g. that one of the counter ions forsuch divalent alkali earth ions can be an ionized form of a compound ofthe invention and the other a typical counter ion such as chloride, ortwo ionized compounds of the invention can serve as counter ions forsuch divalent alkali earth ions, or a doubly ionized compound of theinvention can serve as the counter ion for such divalent alkali earthions). As specific examples, —NR⁸⁰R⁸⁰ is meant to include —NH₂,—NH-alkyl, N-pyrrolidinyl, N-piperazinyl, 4N-methyl-piperazin-1-yl andN-morpholinyl.

In addition to the groups disclosed with respect to the individual termsherein, substituent groups for hydrogens on unsaturated carbon atoms in“substituted” alkene, alkyne, aryl and heteroaryl groups are, unlessotherwise specified, —R⁶⁰, halo, —O⁻M⁺, —OR⁷⁰, —SR⁷⁰, —S⁻M⁺, —NR⁸⁰R⁸⁰,trihalomethyl, —CF₃, —CN, —OCN, —SCN, —NO, —NO₂, —N₃, —SO₂R⁷⁰, —SO₃ ⁻M⁺,—SO₃R⁷⁰, —OSO₂R⁷⁰, —OSO₃ ⁻M⁺, —OSO₃R⁷⁰, —PO₃ ⁻²(M⁺)₂, —P(O)(OR⁷⁰)O⁻M⁺,—P(O)(OR⁷⁰)₂, —C(O)R⁷⁰, —C(S)R⁷⁰, —C(NR⁷⁰)R⁷⁰, —CO₂ ⁻M⁺, —CO₂R⁷⁰,—C(S)OR⁷⁰, —C(O)NR⁸⁰R⁸⁰, —C(NR⁷⁰)NR⁸⁰R⁸⁰, —OC(O)R⁷⁰, —OC(S)R⁷⁰, —OCO₂⁻M⁺, —OCO₂R⁷⁰, —OC(S)OR⁷⁰, —NR⁷⁰C(O)R⁷⁰, —NR⁷⁰C(S)R⁷⁰, —NR⁷⁰CO₂ ⁻M⁺,—NR⁷⁰CO₂R⁷⁰, —NR⁷⁰C(S)OR⁷⁰, —NR⁷⁰C(O)NR⁸⁰R⁸⁰, —NR⁷⁰C(NR⁷⁰)R⁷⁰ and—NR⁷⁰C(NR⁷⁰)NR⁸⁰R⁸⁰, where R⁶⁰, R⁷⁰, R⁸⁰ and M⁺ are as previouslydefined, provided that in case of substituted alkene or alkyne, thesubstituents are not —O⁻M⁺, —OR⁷⁰, —SR⁷⁰, or —S⁻M⁺.

In addition to the disclosure herein, substituent groups for hydrogenson nitrogen atoms in “substituted” heteroalkyl and cycloheteroalkylgroups are, unless otherwise specified, —R⁶⁰, —O⁻M⁺, —OR⁷⁰, —SR⁷⁰,—S⁻M⁺, —NR⁸⁰R⁸⁰, trihalomethyl, —CF₃, —CN, —NO, —NO₂, —S(O)₂R⁷⁰,—S(O)₂O⁻M⁺, —S(O)₂OR⁷⁰, —OS(O)₂R⁷⁰, —OS(O)₂O⁻M⁺, —OS(O)₂OR⁷⁰,−P(O)(O⁻)₂(M⁺)₂, —P(O)(OR⁷⁰)O⁻M⁺, —P(O)(OR⁷⁰)(OR⁷⁰), —C(O)R⁷⁰, —C(S)R⁷⁰,—C(NR⁷⁰)R⁷⁰, —C(O)OR⁷⁰, —C(S)OR⁷⁰, —C(O)NR⁸⁰R⁸⁰, —C(NR⁷⁰)NR⁸⁰R⁸⁰,—OC(O)R⁷⁰, —OC(S)R⁷⁰, —OC(O)OR⁷⁰, —OC(S)OR⁷⁰, —NR⁷⁰C(O)R⁷⁰,—NR⁷⁰C(S)R⁷⁰, —NR⁷⁰C(O)OR⁷⁰, —NR⁷⁰C(S)OR⁷⁰, —NR⁷⁰C(O)NR⁸⁰R⁸⁰,—NR⁷⁰C(NR⁷⁰)R⁷⁰ and —NR⁷⁰C(NR⁷⁰)NR⁸⁰R⁸⁰, where R⁶⁰, R⁷⁰, R⁸⁰ and M⁺ areas previously defined.

In addition to the disclosure herein, in a certain embodiment, a groupthat is substituted has 1, 2, 3, or 4 substituents, 1, 2, or 3substituents, 1 or 2 substituents, or 1 substituent.

It is understood that in all substituted groups defined above, polymersarrived at by defining substituents with further substituents tothemselves (e.g., substituted aryl having a substituted aryl group as asubstituent which is itself substituted with a substituted aryl group,which is further substituted by a substituted aryl group, etc.) are notintended for inclusion herein. In such cases, the maximum number of suchsubstitutions is three. For example, serial substitutions of substitutedaryl groups are limited to substituted aryl-(substitutedaryl)-substituted aryl.

Unless indicated otherwise, the nomenclature of substituents that arenot explicitly defined herein are arrived at by naming the terminalportion of the functionality followed by the adjacent functionalitytoward the point of attachment. For example, the substituent“arylalkyloxycarbonyl” refers to the group (aryl)-(alkyl)-O—C(O)—.

As to any of the groups disclosed herein which contain one or moresubstituents, it is understood, of course, that such groups do notcontain any substitution or substitution patterns which are stericallyimpractical and/or synthetically non-feasible. In addition, the subjectcompounds include all stereochemical isomers arising from thesubstitution of these compounds.

The term “salt thereof” means a compound formed when the hydrogen of anacid is replaced by a cation, such as a metal cation or an organiccation and the like. Where applicable, the salt is a pharmaceuticallyacceptable salt, although this is not required for salts of compoundsthat are not intended for administration to a patient. By way ofexample, salts of the present compounds include those wherein thecompound is protonated by an inorganic or organic acid to form a cation,with the conjugate base of the inorganic or organic acid as the anioniccomponent of the salt.

“Solvate” refers to a complex formed by combination of solvent moleculeswith molecules or ions of the solute. The solvent can be an organiccompound, an inorganic compound, or a mixture of both. Some examples ofsolvents include, but are not limited to, methanol,N,N-dimethylformamide, tetrahydrofuran, dimethylsulfoxide, and water.When the solvent is water, the solvate formed is a hydrate.

“Stereoisomer” and “stereoisomers” refer to compounds that have sameatomic connectivity but different atomic arrangement in space.Stereoisomers include cis-trans isomers, E and Z isomers, enantiomers,and diastereomers.

“Tautomer” refers to alternate forms of a molecule that differ only inelectronic bonding of atoms and/or in the position of a proton, such asenol-keto and imine-enamine tautomers, or the tautomeric forms ofheteroaryl groups containing a —N═C(H)—NH— ring atom arrangement, suchas pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles. Aperson of ordinary skill in the art would recognize that othertautomeric ring atom arrangements are possible.

It will be appreciated that the term “or a salt or solvate orstereoisomer thereof” is intended to include all permutations of salts,solvates and stereoisomers, such as a solvate of a pharmaceuticallyacceptable salt of a stereoisomer of subject compound.

Representative Embodiments

The following substituents and values are intended to providerepresentative examples of various aspects and embodiments. Theserepresentative values are intended to further define and illustrate suchaspects and embodiments and are not intended to exclude otherembodiments or to limit the scope of this invention. In this regard, therepresentation that a particular value or substituent is preferred isnot intended in any way to exclude other values or substituents fromthis invention unless specifically indicated.

These compounds may contain one or more chiral centers and therefore,the embodiments are directed to racemic mixtures; pure stereoisomers(i.e., enantiomers or diastereomers); stereoisomer-enriched mixtures andthe like unless otherwise indicated. When a particular stereoisomer isshown or named herein, it will be understood by those skilled in the artthat minor amounts of other stereoisomers may be present in thecompositions unless otherwise indicated, provided that the desiredutility of the composition as a whole is not eliminated by the presenceof such other isomers.

The compounds described also include isotopically labeled compoundswhere one or more atoms have an atomic mass different from the atomicmass conventionally found in nature. Examples of isotopes that may beincorporated into the compounds disclosed herein include, but are notlimited to, ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, etc. Thus, thedisclosed compounds may be enriched in one or more of these isotopesrelative to the natural abundance of such isotope. By way of example,deuterium (²H) has a natural abundance of about 0.015%. Accordingly, forapproximately every 6,500 hydrogen atoms occurring in nature, there isone deuterium atom. Specifically contemplated herein are compoundsenriched in deuterium at one or more positions. Thus, deuteriumcontaining compounds of the disclosure have deuterium at one or morepositions (as the case may be) in an abundance of greater than 0.015%.

Protected Cyclopropylboronic Acids

This disclosure concerns a protected cyclopropylboronic acid comprisinga substituted cyclopropyl group and a boronic ester group having aprotecting group. The protecting group is an N-methyliminodiacetic acid(MIDA) group or MIDA-based group.

The protected cyclopropylboronic acid can undergo deprotection undermild conditions with high yields. Such a system can control thereactivity of boronic acids and expand the versatility of the Suzukireaction or of other reactions of boronic acids. Thus, the protectedcyclopropylboronic acid can deliver a substituted cyclopropyl group in acoupling reaction with improved selectivity compared to a correspondingreaction without use of the protected cyclopropylboronic acid.

A cyclopropylboronic acid has a general structure:

wherein R is a cyclopropyl group that is bonded to the boron through aboron-carbon bond, wherein the cyclopropyl group has at least onesubstituent.

A protected cyclopropylboronic acid is a chemical transform of acyclopropylboronic acid, in which the boron has a lower chemicalreactivity relative to the original cyclopropylboronic acid. A protectedcyclopropylboronic acid has a general structure:

wherein R^(a) and R^(b) are independently hydrogen or an organic group,as defined herein and examples of which are alkyl, acyl, cycloalkyl,aryl and the like;

wherein at least one of R^(a) and R^(b) is not hydrogen; and

R is a cyclopropyl group that is bonded to the boron through aboron-carbon bond, wherein the cyclopropyl group has at least onesubstituent.

A protected cyclopropylboronic acid can also be referred to as acyclopropylboronate or cyclopropylboronic ester.

This disclosure concerns a protected cyclopropylboronic acid comprisinga substituted cyclopropyl group and a boronic ester group having a MIDAor MIDA-based protecting group, as shown in the formulae below:

Formula I

One embodiment provides a protected organoboronic acid of the formula I:

wherein

R¹ is selected from hydrogen, alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, aryl, and heteroaryl;and

R^(2a), R^(2b), R^(2c), and R^(2d) are independently selected fromhydrogen, alkyl, substituted alkyl, halogen, hydroxyl, cyano, phosphate,alkoxy, substituted alkoxy, carboxyl, carboxyl ester, aryl, substitutedaryl, heteroaryl, substituted heteroaryl, heterocyclyl, substitutedheterocyclyl, alkenyl, substituted alkenyl, amino, substituted amino,acyl, acylamino, aminoacyl, alkoxycarbonylamino, thiol, alkylthiol,substituted thioalkoxy, and sulfonyl, wherein at least one of R^(2a),R^(2b), R^(2c), and R^(2d) is not hydrogen.

In formula I, R¹ is selected from hydrogen, alkyl, substituted alkyl,alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, andheteroaryl. In certain embodiments, R¹ is alkyl or substituted alkyl. Incertain embodiments, R¹ is alkyl. In certain embodiments, R¹ is methyl.In certain embodiments, R¹ is substituted alkyl. In certain embodiments,R¹ is hydrogen.

In certain embodiments, R¹ is alkenyl or substituted alkenyl. In certainembodiments, R¹ is alkynyl or substituted alkynyl. In certainembodiments, R¹ is aryl or heteroaryl.

In formula I, R^(2a), R^(2b), R^(2c), and R^(2d) are independentlyselected from hydrogen, alkyl, substituted alkyl, halogen, hydroxyl,cyano, phosphate, alkoxy, substituted alkoxy, carboxyl, carboxyl ester,aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclyl, substituted heterocyclyl, alkenyl, substituted alkenyl,amino, substituted amino, acyl, acylamino, aminoacyl,alkoxycarbonylamino, thiol, alkylthiol, substituted thioalkoxy, andsulfonyl, wherein at least one of R^(2a), R^(2b), R^(2c), and R^(2d) isnot hydrogen.

In certain embodiments, at least one of R^(2a), R^(2b), R^(2c), andR^(2d) is alkyl or substituted alkyl and the others are hydrogen. Incertain embodiments, one of R^(2a), R^(2b), R^(2c), and R^(2d) is alkylor substituted alkyl and the others are hydrogen.

In certain embodiments, at least one of R^(2a), R^(2b), R^(2c), andR^(2d) is substituted alkyl and the others are hydrogen. In certainembodiments, one of R^(2a), R^(2b), R^(2c), and R^(2d) is substitutedalkyl and the others are hydrogen. In certain embodiments, at least oneof R^(2a), R^(2b), R^(2c), and R^(2d) is trifluoromethyl and the othersare hydrogen. In certain embodiments, one of R^(2a), R^(2b), R^(2c) andR^(2d) is trifluoromethyl and the others are hydrogen. In certainembodiments, at least one of R^(2a), R^(2b), R^(2c), and R^(2d) is alkyland the others are hydrogen. In certain embodiments, one of R^(2a)R^(2b), R^(2c), and R^(2d) is alkyl and the others are hydrogen.

In certain embodiments, at least one of R^(2a), R^(2b), R^(2c), andR^(2d) is halogen, hydroxyl, cyano, or phosphate, and the others arehydrogen. In certain embodiments, at least one of R^(2a), R^(2b),R^(2c), and R^(2d) is alkoxy or substituted alkoxy, and the others arehydrogen. In certain embodiments, at least one of R^(2a), R^(2b),R^(2c), and R^(2d) is carboxyl or carboxyl ester, and the others arehydrogen. In certain embodiments, at least one of R^(2a), R^(2b),R^(2c), and R^(2d) is aryl or substituted aryl, and the others arehydrogen. In certain embodiments, at least one of R^(2a), R^(2b),R^(2c), and R^(2d) is heteroaryl, substituted heteroaryl, heterocyclyl,or substituted heterocyclyl, and the others are hydrogen. In certainembodiments, at least one of R^(2a), R^(2b), R^(2c), and R^(2d) isalkenyl or substituted alkenyl, and the others are hydrogen. In certainembodiments, at least one of R^(2a), R^(2b), R^(2c), and R^(2d) is aminoor substituted amino, and the others are hydrogen. In certainembodiments, at least one of R^(2a), R^(2b), R^(2c), and R^(2d) is acyl,acylamino, aminoacyl, or alkoxycarbonylamino, and the others arehydrogen. In certain embodiments, at least one of R^(2a), R^(2b),R^(2c), and R^(2d) is thiol, alkylthiol, substituted thioalkoxy, andsulfonyl and the others are hydrogen.

Formula II

One embodiment provides a protected organoboronic acid of the formulaII:

wherein

R¹ is selected from hydrogen, alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, aryl, and heteroaryl;and

R^(2a) and R^(2c) are independently selected from alkyl, substitutedalkyl, halogen, hydroxyl, cyano, phosphate, alkoxy, substituted alkoxy,carboxyl, carboxyl ester, aryl, substituted aryl, heteroaryl,substituted heteroaryl, heterocyclyl, substituted heterocyclyl, alkenyl,substituted alkenyl, amino, substituted amino, acyl, acylamino,aminoacyl, alkoxycarbonylamino, thiol, alkylthiol, substitutedthioalkoxy, and sulfonyl.

In formula II, R¹ is selected from hydrogen, alkyl, substituted alkyl,alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, andheteroaryl. In certain embodiments, R¹ is alkyl or substituted alkyl. Incertain embodiments, R¹ is alkyl. In certain embodiments, R¹ is methyl.In certain embodiments, R¹ is substituted alkyl. In certain embodiments,R¹ is hydrogen.

In certain embodiments, R¹ is alkenyl or substituted alkenyl. In certainembodiments, R¹ is alkynyl or substituted alkynyl. In certainembodiments, R¹ is aryl or heteroaryl.

In formula II, R^(2a) is selected from alkyl, substituted alkyl,haloalkyl, halogen, hydroxyl, cyano, phosphate, alkoxy, substitutedalkoxy, carboxyl, carboxyl ester, aryl, substituted aryl, heteroaryl,substituted heteroaryl, heterocyclyl, substituted heterocyclyl, alkenyl,substituted alkenyl, amino, substituted amino, acyl, acylamino,aminoacyl, alkoxycarbonylamino, thiol, alkylthiol, substitutedthioalkoxy, and sulfonyl.

In certain embodiments, R^(2a) is alkyl or substituted alkyl. In certainembodiments, R^(2a) is substituted alkyl. In certain embodiments, R^(2a)is trifluoromethyl. In certain embodiments, R^(2a) is alkyl.

In certain embodiments, R^(2a) is halogen, hydroxyl, cyano, orphosphate. In certain embodiments, R^(2a) is alkoxy or substitutedalkoxy. In certain embodiments, R^(2a) is carboxyl or carboxyl ester. Incertain embodiments, R^(2a) is aryl or substituted aryl. In certainembodiments, R^(2a) is heteroaryl, substituted heteroaryl, heterocyclyl,or substituted heterocyclyl. In certain embodiments, R^(2a) is alkenylor substituted alkenyl. In certain embodiments, R^(2a) is amino orsubstituted amino. In certain embodiments, R^(2a) is acyl, acylamino,aminoacyl, or alkoxycarbonylamino. In certain embodiments, R^(2a) isthiol, alkylthiol, substituted thioalkoxy, and sulfonyl.

In formula II, R^(2c) is selected from alkyl, substituted alkyl,haloalkyl, halogen, hydroxyl, cyano, phosphate, alkoxy, substitutedalkoxy, carboxyl, carboxyl ester, aryl, substituted aryl, heteroaryl,substituted heteroaryl, heterocyclyl, substituted heterocyclyl, alkenyl,substituted alkenyl, amino, substituted amino, acyl, acylamino,aminoacyl, alkoxycarbonylamino, thiol, alkylthiol, substitutedthioalkoxy, and sulfonyl.

In certain embodiments, R^(2c) is alkyl or substituted alkyl. In certainembodiments, R^(2c) is substituted alkyl. In certain embodiments, R^(2a)is trifluoromethyl. In certain embodiments, R^(2c) is alkyl.

In certain embodiments, R^(2c) is halogen, hydroxyl, cyano, orphosphate. In certain embodiments, R^(2c) is alkoxy or substitutedalkoxy. In certain embodiments, R^(2c) is carboxyl or carboxyl ester. Incertain embodiments, R^(2c) is aryl or substituted aryl. In certainembodiments, R^(2c) is heteroaryl, substituted heteroaryl, heterocyclyl,or substituted heterocyclyl. In certain embodiments, R^(2c) is alkenylor substituted alkenyl. In certain embodiments, R^(2c) is amino orsubstituted amino. In certain embodiments, R^(2c) is acyl, acylamino,aminoacyl, or alkoxycarbonylamino. In certain embodiments, R^(2c) isthiol, alkylthiol, substituted thioalkoxy, and sulfonyl.

In certain embodiments, the protected organoboronic acid of the formulaII has a trans stereochemistry with respect to the cyclopropyl ring. Forexample, the trans isomer of the protected organoboronic acid of formulaII has the structure, shown below:

A composition can comprise a mixture of diastereomers, or a racemicmixture of a single diastereomer of the protected organoboronic acidabove. Alternatively, such racemic mixtures can be resolved bytechniques known to those of skill in the art of organic synthesis, orcompounds of the formula above can be prepared in optically active formas is known to those of skill in the art.

In certain embodiments, the protected organoboronic acid of the formulaII has a trans stereochemistry with respect to one or more substituentson the cyclopropyl ring. The protected organoboronic acid may also havea cis relationship with one or more substituents on the cyclopropyl ringof formula II. An example of such a structure having both a cis and atrans substituent relative to the protected organoboronic acid isillustrated by the structure, shown below:

wherein R^(2a) and R^(2c) are trans and cis, respectively, relative tothe boron substituent. A composition can comprise a racemic mixture ofstereoisomers of the protected organoboronic acid of the formula above.Alternatively, compounds of the formula above can be prepared inoptically active form or can be resolved to provide an optically activecompound.

In certain embodiments, the protected organoboronic acid of the formulaII is trans with respect to one or more substituents on the cyclopropylring. One example of such a protected organoboronic acid of formula IIis illustrated by the structure shown below:

wherein, R^(2a) and R^(2c) are trans relative to the boron substituent.A composition can comprise a racemic mixture of a single diastereomer ofthe protected organoboronic acid of formula II.

Formula III

One embodiment provides a protected organoboronic acid of the formulaIII:

wherein

R¹ is selected from hydrogen, alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, aryl, and heteroaryl;and

R^(2a) is selected from alkyl, substituted alkyl, halogen, hydroxyl,cyano, phosphate, alkoxy, substituted alkoxy, carboxyl, carboxyl ester,aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclyl, substituted heterocyclyl, alkenyl, substituted alkenyl,amino, substituted amino, acyl, acylamino, aminoacyl,alkoxycarbonylamino, thiol, alkylthiol, substituted thioalkoxy, andsulfonyl.

In formula III, R¹ is selected from hydrogen, alkyl, substituted alkyl,alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, andheteroaryl. In certain embodiments, R¹ is alkyl or substituted alkyl. Incertain embodiments, R¹ is alkyl. In certain embodiments, R¹ is methyl.In certain embodiments, R¹ is substituted alkyl. In certain embodiments,R¹ is hydrogen.

In certain embodiments, R¹ is alkenyl or substituted alkenyl. In certainembodiments, R¹ is alkynyl or substituted alkynyl. In certainembodiments, R¹ is aryl or heteroaryl.

In formula III, R^(2a) is selected from alkyl, substituted alkyl,haloalkyl, halogen, hydroxyl, cyano, phosphate, alkoxy, substitutedalkoxy, carboxyl, carboxyl ester, aryl, substituted aryl, heteroaryl,substituted heteroaryl, heterocyclyl, substituted heterocyclyl, alkenyl,substituted alkenyl, amino, substituted amino, acyl, acylamino,aminoacyl, alkoxycarbonylamino, thiol, alkylthiol, substitutedthioalkoxy, and sulfonyl.

In certain embodiments, R^(2a) is alkyl or substituted alkyl. In certainembodiments, R^(2a) is substituted alkyl. In certain embodiments, R^(2a)is trifluoromethyl. In certain embodiments, R^(2a) is alkyl.

In certain embodiments, R^(2a) is halogen, hydroxyl, cyano, orphosphate. In certain embodiments, R^(2a) is alkoxy or substitutedalkoxy. In certain embodiments, R^(2a) is carboxyl or carboxyl ester. Incertain embodiments, R^(2a) is aryl or substituted aryl. In certainembodiments, R^(2a) is heteroaryl, substituted heteroaryl, heterocyclyl,or substituted heterocyclyl. In certain embodiments, R^(2a) is alkenylor substituted alkenyl. In certain embodiments, R^(2a) is amino orsubstituted amino. In certain embodiments, R^(2a) is acyl, acylamino,aminoacyl, or alkoxycarbonylamino. In certain embodiments, R^(2a) isthiol, alkylthiol, substituted thioalkoxy, and sulfonyl.

In certain embodiments, of the protected organoboronic acid of theformula II R^(2a) and the boron substituent have a trans relativestereochemistry. For example, the protected organoboronic acid of theformula III has a structure, shown below:

A composition can comprise racemic mixture of trans stereoisomers of theprotected organoboronic acid of the formula III.

Formula IV

One embodiment provides a protected organoboronic acid of the formulaIV:

In certain embodiments, the protected organoboronic acid of the formulaIV has a trans stereochemistry with respect to the cyclopropyl ring.Such trans relative stereochemistry is illustrated in the structurebelow:

A composition can comprise racemic mixture of trans stereoisomers of theprotected organoboronic acid of the formula IV. Alternatively, suchracemic mixtures can be resolved or compounds of the formula above canbe prepared enantioselectively to provide optically active compositions.

Synthesis of Compounds

Many general references providing commonly known chemical syntheticschemes and conditions useful for synthesizing the disclosed compoundsare available (see, e.g., Smith and March, March's Advanced OrganicChemistry: Reactions, Mechanisms, and Structure, Fifth Edition,Wiley-Interscience, 2001; or Vogel, A Textbook of Practical OrganicChemistry, Including Qualitative Organic Analysis, Fourth Edition, NewYork: Longman, 1978).

Compounds as described herein can be purified by any of the means knownin the art, including chromatographic means, such as HPLC, preparativethin layer chromatography, flash column chromatography and ion exchangechromatography. Any suitable stationary phase can be used, includingnormal and reversed phases as well as ionic resins. Most typically thedisclosed compounds are purified via silica gel and/or aluminachromatography. See, e.g., Introduction to Modern Liquid Chromatography,2nd Edition, ed. L. R. Snyder and J. J. Kirkland, John Wiley and Sons,1979; and Thin Layer Chromatography, ed E. Stahl, Springer-Verlag, NewYork, 1969.

During any of the processes for preparation of the subject compounds, itmay be necessary and/or desirable to protect sensitive or reactivegroups on any of the molecules concerned. This may be achieved by meansof conventional protecting groups as described in standard works, suchas J. F. W. McOmie, “Protective Groups in Organic Chemistry”, PlenumPress, London and New York 1973, in T. W. Greene and P. G. M. Wuts,“Protective Groups in Organic Synthesis”, Third edition, Wiley, New York1999, in “The Peptides”; Volume 3 (editors: E. Gross and J. Meienhofer),Academic Press, London and New York 1981, in “Methoden der organischenChemie”, Houben-Weyl, 4^(th) edition, Vol. 15/1, Georg Thieme Verlag,Stuttgart 1974, in H.-D. Jakubke and H. Jescheit, “Aminosauren, Peptide,Proteine”, Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982,and/or in Jochen Lehmann, “Chemie der Kohlenhydrate: Monosaccharide andDerivate”, Georg Thieme Verlag, Stuttgart 1974. The protecting groupsmay be removed at a convenient subsequent stage using methods known fromthe art.

The subject compounds can be synthesized via a variety of differentsynthetic routes using commercially available starting materials and/orstarting materials prepared by conventional synthetic methods. Suitableexemplary methods that can be routinely adapted to synthesize theprotected cyclopropylboronic acid compounds are found in U.S. PatentPublication Nos. 2009/0030238 and 2010/0121062, the disclosure of whichare incorporated herein by reference in their entireties. All of thecompounds described herein can be prepared by routine adaptation ofthese methods.

Exemplary synthetic methods for the protected cyclopropylboronic acidcompounds described herein are described below. Those of skill in theart will also be able to readily adapt these methods for the synthesisof specific protected cyclopropylboronic acid compounds as describedherein.

Synthesis of Protected Cyclopropylboronic Acids

Protected cyclopropylboronic acids according to formula (1c) can beprepared by cyclopropanation reaction of the corresponding MIDA orMIDA-based protected vinylboronate (1a) with R^(2a)-substituteddiazomethane (1b) under the influence of metal catalysis, as illustratedin the following reaction scheme. Suitable methods to form thecyclopropylboronic acid are found in Tetrahedron Letters 51 (2010)1009-1011, which is hereby incorporated by reference in its entirety.

In the above scheme, R¹ and R^(2a) are previously defined. Compound 1acan be obtained commercially (Sigma-Aldrich, St. Louis, Mo.).

R^(2a)-Substituted diazomethane can be synthesized using standardprocedures to prepare diazo compounds and are usually preparedimmediately before their use. A suitable procedure to prepare a diazocompound is reaction of a nitrite ion with an amino compound to form anN-nitroso group and then an elimination reaction of the N-nitroso groupto form a diazo compound.

Metal catalysis can aid the cyclopropanation reaction. In certainembodiments, the metal catalysis uses palladium, ruthenium, cobalt,copper, iron, osmium, rhenium, and rhodium. In certain embodiments, themetal catalysis uses palladium. In certain embodiments, the metalcatalysis uses palladium acetate.

In certain embodiments, referring the scheme below, a boronate ester(2c) can be formed, for example, by cyclopropanation of dialkylvinylboronate (2a) with (2,2,2-trifluoromethyl)diazomethane (2b) underthe influence of palladium (II) catalysis, such as, but not limited to,palladium (II) acetate.

Substitution on the cyclopropyl ring on Compounds 1c and 2c can beachieved with further reactions as known to a skilled artisan.Substitution on the cyclopropyl ring can also be achieved withappropriate substitution of reactant Compound 1b.

Alternate Synthesis of Protected Cyclopropylboronic Acids

Protected cyclopropylboronic acids according to formula (3c) can beprepared by reaction of an appropriate imino-di-carboxylic acid with thecorresponding unprotected cyclopropylboronic acid (3a), as illustratedin the following reaction scheme:

In a specific example, protected cyclopropylboronic acids according toformula (4c) can be prepared by reaction of N-methyliminodiacetic acid(MIDA) (4b) with the corresponding unprotected cyclopropylboronic acid(4a), as illustrated in the following reaction scheme:

Protected cyclopropylboronic acids according to formula (5c) can beprepared by reaction of an appropriate imino-di-carboxylic acid with thecorresponding unprotected cyclopropylboronic acid (5a), as illustratedin the following reaction scheme:

In the above scheme, R is an alkyl, such as methyl, n-propyl, isopropyl,n-butyl, or cyclized to form pinacolato boronate ester; R¹ is H, Li, Na,or K; and R^(2a), R^(2b), R^(2c), and R^(2d) are as defined herein. Incertain embodiments in the reaction scheme above, the conditions caninclude heating in polar aprotic solvent, such as, but not limited toDMSO or DMF. In certain embodiments, in the reaction scheme above, R¹ isNa.

The protected cyclopropylboronic acid can be formed by condensationunder Dean-Stark conditions. For instance, removal of water underDean-Stark conditions can be condensation with heating of the reactionmixture up to at least about 35-45° C. In certain instances, heating ofthe reaction mixture is up to at least about 40° C. The conditions canalso include the use of a co-solvent, such as DMSO, to partiallydissolve the MIDA or MIDA-based ligand. The removal of water can also beperformed by a variety of techniques, including, but not limited to,molecular sieves, azeotropic drying with acetonitrile.

In each case, the protected cyclopropylboronic acid can be deprotectedby contact with a mild base, to provide the free cyclopropylboronicacid.

Synthesis of Precursor Cyclopropylboronic Acids

Suitable methods to form the compounds 3a, 4a, or 5a above are found inTetrahedron Letters 51 (2010) 1009-1011, which is hereby incorporated byreference in its entirety. Referring to the scheme, thecyclopropylboronate ester (6c) can be formed, for example, bycyclopropanation of dialkyl vinylboronate (6a) with R^(2a)-substituteddiazomethane (6b) under the influence of metal catalysis.

In the above scheme, R^(a) and R^(b) are organic groups as definedherein and R^(2a) is previously defined. In certain instances, R^(a) andR^(b) are alkyl groups, such as methyl, ethyl, propyl, or butyl.

Metal catalysis can aid the cyclopropanation reaction. In certainembodiments, the metal catalysis uses palladium, ruthenium, cobalt,copper, iron, osmium, rhenium, and rhodium. In certain embodiments, themetal catalysis uses palladium. In certain embodiments, the metalcatalysis uses palladium acetate.

In certain embodiments, referring the scheme below, a boronate ester(7c) can be formed, for example, by cyclopropanation of dialkylvinylboronate (7a) with (2,2,2-trifluoromethyl)diazomethane (7b) underthe influence of palladium (II) catalysis, such as, but not limited to,palladium (II) acetate.

In the above schemes concerning cyclopropyl boronic acids (1a) and (2a),cyclopropylboronate esters (6c) and (7c) can be hydrolyzed to formcyclopropyl boronic acids (3a) and (4a). Hydrolysis of boronate esterscan be accomplished in certain systems with thionyl chloride andpyridine.

Alternative Synthesis of Protected Cyclopropylboronic Acids

Protected cyclopropylboronic acids also can be formed without everforming the free cyclopropylboronic acid. For example, a boronic halide(8a) can be reacted with a diacid or its corresponding salt to provideprotected organoboronic acid (8c), as illustrated in the followingreaction scheme:

The boronic halide can be formed by treatment of a silane such as(cyclopropyl)-SiR₃ with BBr₃. (Qin, Y., J. Am. Chem. Soc., 2002, 124,12672-12673 and Qin, Y, Macromolecules, 2004, 37, 7123-7131.)

Protected cyclopropylboronic acids including a MIDA boronate esterprotecting group are readily purified by column chromatography. This isunusual for organoboronic acids, which are typically unstable tochromatographic techniques. These protected cyclopropylboronic acidsalso may be crystalline, which can facilitate purification, utilization,and storage. These protected cyclopropylboronic acids are stable to longterm storage, including storage on the bench top under air. This is alsounusual, as many organoboronic acids are unstable to long term storage.

Although many of the synthetic schemes discussed above do not illustratethe use of protecting groups, skilled artisans will recognize that insome instances certain substituents may include functional groupsrequiring protection. The exact identity of the protecting group usedwill depend upon, among other things, the identity of the functionalgroup being protected and the reaction conditions used in the particularsynthetic scheme, and will be apparent to those of skill in the art.Guidance for selecting protecting groups, their attachment and removalsuitable for a particular application can be found, for example, in T.W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”,Fourth edition, Wiley, New York 2006.

Reactions Using Protected Cyclopropylboronic Acids

As will be readily appreciated by those of skill in the art, thepresently disclosed organoboronic acids are useful in a variety oftransition metal-catalyzed coupling reactions. Examples of suchtransition metal-catalyzed coupling reactions include those catalyzed bypalladium, ruthenium, rhenium, rhodium, and the like. Examples ofpalladium-catalyzed coupling reactions for use with the presentorganoboronic acids include Suzuki reactions with aryl, heteroaryl andaliphatic coupling partners. Similarly, the present organoboronic acidsare useful in rhodium catalyzed reactions, such as addition to sulfinylimine substrates (see, Brak and Ellman, J. Org. Chem. 2010, 75,3147-3150, which is incorporated herein by reference).

According to the embodiments, a Suzuki reaction can be carried out bycoupling of a compound of formulae I-IV with an organohalide ororgano-pseudohalide in the presence of a palladium catalyst and a base,in an appropriate solvent to produce a cross-coupled product.

The protected cyclopropylboronic acid can undergo deprotection undermild conditions with high yields. Such a system can control thereactivity of boronic acids and expand the versatility of the Suzukireaction or of other reactions of boronic acids. Thus, the protectedcyclopropylboronic acid can deliver a substituted cyclopropyl group in acoupling reaction with improved selectivity compared to a correspondingreaction without use of the protected cyclopropylboronic acid.

In certain embodiments, reaction of the protected cyclopropylboronicacid with an organohalide or organo-pseudohalide can deliver asubstituted cyclopropyl group to an organic group and displace a halogenor pseudohalogen group from the organohalide or organo-pseudohalide. Inthe scheme below, a protected cyclopropylboronic acid is coupled with anorganohalide or organo-pseudohalide, R¹⁰—Y, where R¹⁰ is an organicgroup and Y is a halogen or pseudohalogen.

The embodiments provide a method of performing a chemical reactioncomprising: contacting a protected organoboronic acid of formula I:

wherein

R¹ is selected from hydrogen, alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, aryl, and heteroaryl;and

R^(2a), R^(2b), R^(2c), and R^(2d) are independently selected fromhydrogen, alkyl, substituted alkyl, halogen, hydroxyl, cyano, phosphate,alkoxy, substituted alkoxy, carboxyl, carboxyl ester, aryl, substitutedaryl, heteroaryl, substituted heteroaryl, heterocyclyl, substitutedheterocyclyl, alkenyl, substituted alkenyl, amino, substituted amino,acyl, acylamino, aminoacyl, alkoxycarbonylamino, thiol, alkylthiol,substituted thioalkoxy, and sulfonyl, wherein at least one of R^(2a),R^(2b), R^(2c), and R^(2d) is not hydrogen;

with an organohalide or organo-pseudohalide and a metal catalyst, in thepresence of a base to provide a cross-coupled product.

The embodiments provide a method of performing a chemical reactioncomprising: contacting a protected organoboronic acid of formula II:

wherein

R¹ is selected from hydrogen, alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, aryl, and heteroaryl;and

R^(2a) and R^(2c) are independently selected from alkyl, substitutedalkyl, halogen, hydroxyl, cyano, phosphate, alkoxy, substituted alkoxy,carboxyl, carboxyl ester, aryl, substituted aryl, heteroaryl,substituted heteroaryl, heterocyclyl, substituted heterocyclyl, alkenyl,substituted alkenyl, amino, substituted amino, acyl, acylamino,aminoacyl, alkoxycarbonylamino, thiol, alkylthiol, substitutedthioalkoxy, and sulfonyl.

with an organohalide or organo pseudohalide and a metal catalyst, in thepresence of a base to provide a cross-coupled product.

The embodiments provide a method of performing a chemical reactioncomprising: contacting a protected organoboronic acid of formula III:

wherein

R¹ is selected from hydrogen, alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, aryl, and heteroaryl;and

R^(2a) is selected from alkyl, substituted alkyl, halogen, hydroxyl,cyano, phosphate, alkoxy, substituted alkoxy, carboxyl, carboxyl ester,aryl, substituted aryl, heteroaryl, substituted heteroaryl,heterocyclyl, substituted heterocyclyl, alkenyl, substituted alkenyl,amino, substituted amino, acyl, acylamino, aminoacyl,alkoxycarbonylamino, thiol, alkylthiol, substituted thioalkoxy, andsulfonyl;

with an organohalide or organo pseudohalide and a metal catalyst, in thepresence of a base to provide a cross-coupled product.

The embodiments provide a method of performing a chemical reactioncomprising: contacting a protected organoboronic acid of formula IV:

with an organohalide or organo pseudohalide and a metal catalyst, in thepresence of a base to provide a cross-coupled product.

Substrates

The compound with which the protected cyclopropylboronic acid is reactedcan be an organohalide or an organo-pseudohalide. An organohalide is anorganic group having a halogen substituent. An organo-pseudohalide is anorganic group having a pseudohalogen substituent.

An “organic group” or “organic compound” refers a group or compound thatincludes at least one carbon atom, but which may include additionalsubstituent or functional groups, such as amino, alkoxy, cyano, hydroxy,carboxy, halo, acyl, oxo, hydrazino, alkyl, cycloalkyl, hetaryl, aryl,allylic, vinylic, arylene, benzylic, carboxyl, carboxyl ester,derivatives thereof, and the like. Organic groups and organic compoundscan be cyclic or acyclic. Although an organic group or organic compoundutilized herein can have essentially any number of carbon atoms, organicgroups or organic compounds typically include about 2-20 carbon atoms,and more typically include about 3-15 carbon atoms. In certainembodiments, aryl, heteroaryl or aliphatic coupling partners are used.

A halogen or halide refers to —F, —Cl, —Br or —I. A pseudohalogen orpseudohalide refers to a polyatomic anion that resembles a halide ion inits acid-base, substitution, and redox chemistry, generally has lowbasicity, and forms a free radical under atom transfer radicalpolymerization conditions.

The substrate compound can be an organohalide, which is an organiccompound that includes at least one halogen group. Examples of halogengroups that can be present in an organohalide compound include —F, —Cl,—Br or —I. The compound can be an organo-pseudohalide, which is anorganic compound that includes at least one pseudohalogen group.Examples of pseudohalogen groups that can be present in anorgano-pseudohalide compound include triflate (—O—S(═O)₂—CF₃),methanesulfonate (—O—S(═O)₂—CH₃), cyanate (—C≡N), azide (—N₃),thiocyanate (—N═C═S), thioether (—S—R), anhydride (—C(═O)—O—C(═O)—R),phenyl selenide (—Se—C₆Hs), alkoxy (—OR, e.g., OMe), diazo (—N₂),tosylate (—OTs), nonaflate (—ONf), and phosphonate (—OP(O)(OR)₂)

The halogen or pseudo-halogen group may be bonded to a carbon atom of acompound.

In certain embodiments, a substrate compound is of the formula:

wherein X is a halide or pseudohalide and R¹ is carboxyl, carboxylester, or acyl.

In certain embodiments, a substrate compound is of the formula:

wherein X is a halide or pseudohalide.

In certain embodiments, a substrate compound is of the formula:

wherein X is a halide or pseudohalide and R¹ is carboxyl ester.

In certain embodiments, a substrate compound is of the formula:

wherein X is a halide or pseudohalide.

In certain embodiments, a substrate compound is of the formula:

wherein X is a halide or pseudohalide.

In certain embodiments, a substrate compound is of the formula:

wherein X is a halide or pseudohalide; and R¹, R², R³, and R⁴ are eachindependently hydrogen, alkyl, aryl, heteroaryl, or acyl.

Palladium Catalyst

Typically, the Suzuki reaction can be carried out in the presence of apalladium catalyst. Examples of palladium catalysts and catalystprecursors include, but are not limited to palladium(II) acetate,palladium on activated charcoal, tetrakis(triphenylphosphine)palladium(0), and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II).

In certain embodiments, the catalyst is formed in situ frompalladium(II) acetate or palladium on activated charcoal. Palladium(II)acetate can be used in combination with a2-(dicyclohexylphosphino)biphenyl type ligand (J. P. Wolfe et al., J.Am. Chem. Soc., 1999, 121, 9550-9561, which is hereby incorporated byreference in its entirety). The catalyst or catalyst precursor can alsobe encapsulated, such as for example the Pd EnCat™ type catalysts.

In certain embodiments, the reaction can employ ligand selected from: atrialkyl phosphine, a triarylphosphine, or a combination thereof, morespecifically suitable ligands include triphenylphosphine,tri-o-tolylphosphine, tri-m-tolylphosphine, tri-p-tolylphosphine,tricyclohexylphosphine, tri-t-butylphosphine or a combination thereof.For an exemplary method for using tricyclohexylphosphine see,Tetrahedron Letters 2002, 43, 6987-6890. The ligand can be added as apart of a metal complex, such as a palladium-ligand complex, may beadded separately from a metal catalyst or catalyst precursor, or both.

Base

The base used to deprotect the MIDA cyclopropylboronate and promote thecross-coupling reaction can be a mild base. Deprotection of MIDAcyclopropylboronates with a mild base can provide a slower release ofthe unprotected cyclopropylboronic acid into the reaction mixture thanthat provided through deprotection with a strong base. This slowerrelease can allow cross-coupling to occur between an organohalide or anorgano-pseudohalide and a cyclopropylboronic acid that would otherwisedegrade during the reaction. This slower release also can allowcross-coupling to occur with cyclopropylboronic acids that cannot beprepared or isolated in pure form.

In certain embodiments, the base is an anion selected from [PO₄]³⁻,[C₆H₅O]⁻, [CO₃]²⁻ and [HCO₃]¹⁻, such as alkali and alkaline earth saltsof these anions. Certain examples of such bases include Li₃PO₄, Na₃PO₄,K₃PO₄, Li³⁰ [C₆H₅O]—, Na⁺[C₆H₅O]—, K⁺[C₆H₅O]—, Li₂CO₃, Na₂CO₃, K₂CO₃,MgCO₃, CaCO₃, LiHCO₃, NaHCO₃, KHCO₃, and Cs₂CO₃.

In a Suzuki reaction, the reaction can include contacting the protectedcyclopropylboronic acid and the organohalide or organo-pseudohalide witha palladium catalyst in the presence of a mild base. The protectinggroup can be removed from the boron atom in situ, providing acorresponding unprotected cyclopropylboronic acid, which can thencross-couple with the organohalide or organo-pseudohalide. In certainembodiments, the removal of the protecting group, such as a MIDA groupor MIDA-based group, and the contacting of the resulting organoboronicacid and an organohalide or organo pseudohalide with a metal catalystare performed simultaneously in the presence of a base. In certainembodiments, the removal of the protecting group, such as a MIDA groupor a MIDA-based group, is performed prior to the contacting of theorganoboronic acid and an organohalide or organo pseudohalide with ametal catalyst.

Solvent

The Suzuki reaction is typically run in an aprotic polar solvent or aprotic polar solvent. For example, suitable aprotic polar solventsinclude, but are not limited to, acetonitrile, N,N-dimethylformamide,dimethoxyethane, tetrahydrofuran, dioxane, toluene, and xylene. Incertain embodiments, the aprotic polar solvent is acetonitsrile,N,N-dimethylformamide, dimethoxyethane, or tetrahydrofuran. Suitableprotic polar solvent include, but are not limited to, methanol, ethanol,butanol, n-propanol, isopropanol or a mixture of these solvents withwater. In certain embodiments, the protic polar solvent is n-propanol,isopropanol or a mixture of these solvents with water.

Suzuki Reaction Conditions

The Suzuki reaction is preferably carried out under an inert atmosphere,for example under an argon or nitrogen atmosphere.

Forming a cross-coupled product in the reaction mixture can includemaintaining the reaction mixture at a temperature and for a timesufficient to form a cross-coupled product. For example, forming across-coupled product in the reaction mixture can include maintainingthe reaction mixture at a temperature from about 0 to 200° C. In certainembodiments, the forming includes maintaining the reaction mixture at atemperature from about 25 to 150° C. or from about 50 to 120° C. Forminga cross-coupled product in the reaction mixture can include maintainingthe reaction mixture for a period of about 1 hour to 100 hours. Incertain embodiments, the forming includes maintaining the reactionmixture for a period of about 2 hours to 72 hours or about 4 hours to 48hours. In certain embodiments, the forming a cross-coupled product inthe reaction mixture includes maintaining the reaction mixture at atemperature from about 25 to 150° C. for a period of about 2 hours to 72hours, or maintaining the reaction mixture at a temperature from about50 to 120° C. for a period of from about 4 hours to 48 hours. Inparticular, microwave heating can be used to promote the reactionsdescribed herein.

One skilled in the art will be able to modify these conditions, inparticular by applying the variants of the Suzuki reaction which aredescribed in the literature (N. Miyaura & A. Suzuki, Chem. Rev., 1995,95, 2457-2483; A. Suzuki, J. Organomet. Chem., 1999, 576, 147-168, whichis hereby incorporated by reference in its entirety).

Stereochemistry of Products

The method according to the embodiments is therefore simple andeconomical. The method can make it possible to directly obtain a productcompound with a high yield and favoring a certain stereochemistry.

In certain embodiments, the Suzuki reaction uses a protectedorganoboronic acid of the formula III-IV with a trans stereochemistrywith respect to the cyclopropyl ring. The favored product compound fromthe reaction comprises a trans stereochemistry with respect to thesubstituents on the cyclopropyl ring. For example, the scheme belowshows a general reaction which uses a trans stereoisomer of a protectedorganoboronic acid of the formula III-IV, resulting in a favored productcompound comprising a trans stereochemistry with respect to thesubstituents on the cyclopropyl ring.

In certain embodiments, with use of a protected organoboronic acid ofthe formula III-IV with a trans stereochemistry with respect to thecyclopropyl ring, the stereochemistry ratio (trans:cis) of the productis about 100 to 0; 99 to 1; 98 to 2; 97 to 3; 96 to 4; 95 to 5; 94 to 6;93 to 7; 92 to 8; 91 to 9; 90 to 10; 85 to 15; 80 to 20; 75 to 25; 70 to30; 65 to 45; 60 to 40; or 55 to 45.

EXAMPLES

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how tomake and use the embodiments, and are not intended to limit the scope ofwhat the inventors regard as their invention nor are they intended torepresent that the experiments below are all or the only experimentsperformed. Efforts have been made to ensure accuracy with respect tonumbers used (e.g. amounts, temperature, etc.) but some experimentalerrors and deviations should be accounted for. Unless indicatedotherwise, parts are parts by weight, molecular weight is weight averagemolecular weight, temperature is in degrees Celsius, and pressure is ator near atmospheric. Standard abbreviations may be used.

Example 1 Preparation of trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester

Step 1: Preparation of trifluoromethyl diazomethane

Sodium nitrite (4.6 g, 66 mmol) in water (10 mL) was added in oneportion to a stirred solution of 2,2,2-trifluoroethylamine hydrochloride(8.1 g, 60 mmol) in water (25 mL) and ether (45 mL) at 0° C. Thereaction vessel was sealed with a teflon stopper and the mixture stirredfrom 0° C. to room temperature and stirred at room temperature forapproximately 3 hours. The mixture was then partitioned in a separatingfunnel and the ether layer containing the product was used directly inthe next step without further purification. The yield of thetrifluoromethyl diazomethane product was assumed to be approximately 50%based on literature citation herein (=3.32 g).

A safety notice for the procedure: Diazo compounds are potentiallyexplosive. The reaction was performed behind a blast shield in glasswarefree from cracks or prominent scratches and glassware was inspectedprior to use.

Reference for the procedure is made to J. Am. Chem. Soc. 1943, 65, 1458,which is hereby incorporated by reference in its entirety.

Step 2: Preparation of trans-2-(trifluoromethyl)cyclopropylboronic acidMIDA ester

A mixture of trifluoromethyl diazomethane (3.32 g, 30 mmol) in Et₂O (45mL) was added dropwise to a stirred suspension of vinylboronic acid MIDAester (Sigma-Aldrich, St. Louis, Mo.; 1.65 g, 9.0 mmol) and Pd(OAc)₂ (50mg) in Et₂O at room temperature. After adding for 10 minutes (about aquarter of the trifluoromethyl diazomethane had been added at thisstage), more Pd(OAc)₂ (50 mg) and Et₂O (100 mL) was added, andtrifluoromethyl diazomethane was added dropwise for another 20 minutes(approximately three quarters added after this time). EtOAc (50 mL) andPd(OAc)₂ (50 mg) were added at this point and the remainingtrifloromethyl diazomethane was added dropwise over 10 minutes. Aftercomplete addition of the trifloromethyl diazomethane the mixture wasanalysed by TLC which indicated complete reaction. The solvent wasremoved under vacuum and the residue was dry-loaded on to silica gel andpurified by column chromatography on silica gel using EtOAc as eluent togive the product (1.45 g, 61%) as a solid. A sample was recrystallisedfrom EtOAc, and then a small sample recrystallized again from1,2-dichloroethane, to give crystals suitable for analysis by X-raycrystallography. X-ray studies indicated confirmed the material to bethe trans-isomer.

Reference for the procedure is made to Tetrahedron Letters 2010, 51,1009-1011, which is hereby incorporated by reference in its entirety.

¹H NMR (DMSO-d₆, 300 MHz): δ 3.99-3.72 (m, 4H), 2.70 (s, 3H), 1.28 (m,1H), 0.53 (m, 1H), 0.31 (m, 1H), 0.00 (m, 1H). ¹⁹F NMR (DMSO-d₆, 282MHz): −65.4 (d J=5.9 Hz)

Example 2 Synthesis OFtrans-1-(4-fluoro-5-(5-flouro-4-(2,2,6,6-tetramethylpiperidin-4-ylamino)pyrimidin-2-ylamino)-2-(2-(trifluoromethyl)cyclopropyl)phenyl)-4-methyl-1H-tetrazol-5(4H)-one

Preparation oftrans-1-(4-fluoro-2-(2-(trifluoromethyl)cyclopropyl)-5-nitrophenyl)-4-methyl-1H-tetrazol-5(4H)-one

A mixture of1-(2-bromo-4-fluoro-5-nitrophenyl)-4-methyl-1H-tetrazol-5(4H)-one (145mg, 0.46 mmol), trans-2-(trifluoromethyl)cyclopropylboronic acid MIDAester (240 mg, 0.91 mmol), Pd(OAc)₂ (20 mg, 0.09 mmol), Cy₃P (50 mg,0.18 mmol) and Cs₂CO₃ (593 mg, 1.82 mmol) in toluene (6 mL) and H₂O (2mL) was de-gassed with N₂ for 10 minutes, then placed under a nitrogenatmosphere and heated to 80° C. overnight (a reflux condenser was usedin the apparatus). After completion of the reaction (Note: TLC showedproduct and starting material to be very close), the mixture was cooledand partitioned between EtOAc (50 mL) and H₂O (50 mL). The aqueous andorganic layers were partitioned and the organic layer was washed withbrine (1×20 mL), dried (MgSO₄), filtered and the solvent removed undervacuum to leave a crude residue. The residue was dry-loaded on to silicagel and purified by column chromatography on silica gel usingEtOAc/hexane (3:7 to 4:6) as eluent to give the product (107 mg, 67%).Note: the above reaction was repeated on a larger scale using 4.5 g ofvinylboronic acid MIDA ester and scaling other reagents as appropriateto give the product (5.65 g, 87%) as a solid.

The above reaction was also undertaken starting with 106 mg of1-(2-bromo-4-fluoro-5-nitrophenyl)-4-methyl-1H-tetrazol-5(4H)-one togive the product (55 mg, 47%).

¹H NMR (CDCl₃, 300 MHz): δ 8.19 (dd, 1H), 7.22 (d, 1H), 3.74 (s, 3H),2.69-2.62 (m, 1H), 1.78-1.69 (m, 1H), 1.50-1.43 (m, 1H), 1.29-1.22 (m,1H). ¹⁹F NMR (CDCl₃, 282 MHz): −67.6 (d, J=6.2 Hz), −112.9 (dd, J=7.1,7.1 Hz). m/z=389.2 (M+MeCN+H)⁺

Preparation oftrans-1-(5-amino-4-fluoro-2-(2-(trifluoromethyl)cyclopropyl)phenyl)-4-methyl-1H-tetrazol-5(4H)-one

Palladium on charcoal, wet (Degussa grade E101; 29 mg) was added to amixture oftrans-1-(4-fluoro-2-(2-(trifluoromethyl)cyclopropyl)-5-nitrophenyl)-4-methyl-1H-tetrazol-5(4H)-one(145 mg, 0.46 mmol), EtOH (10 mL) and AcOH (75 μL) under nitrogen. Themixture was evacuated and filled with hydrogen—this procedure wasrepeated another two times. The mixture was hydrogenated at 30 psi for 7days (topping-off the hydrogen if necessary). More Pd on charcoal, wet(Degussa grade E101; 15 mg) was added and the mixture hydrogenated at 30psi for another 10 days (LC/MS was used to monitor the progression ofthe reaction over the 2 week experiment). After complete reaction, themixture was filtered through a small plug of Celite and the filter cakewashed with EtOH (3×10 mL). The filtrate was concentrated under vacuum(dry-loaded on to silica) and purified by column chromatography onsilica gel using EtOAc/hexane (1:4 to 2:3) as eluent to give the product(117 mg, 89%) as a solid.

¹H NMR (d₆-DMSO, 300 MHz): δ 6.99 (d, 1H), 6.78 (dd, 1H), 5.53 (br. s,2H), 3.58 (s, 3H), 2.18-2.11 (m, 1H), 1.92-1.87 (m, 1H), 1.23-1.09 (m,2H). ¹⁹F NMR (d₆-DMSO, 282 MHz): −65.5, −132.0. m/z=318.1 (M+H)⁺

Preparation oftrans-1-(5-(4-(2,2,6,6-tetramethylpiperidin-4-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluoro-2(2-(trifluoromethyl)cyclopropyl)phenyl)-4-methyl-1H-tetrazol-5(4H)-one

A mixture oftrans-1-(5-amino-4-fluoro-2-(2-(trifluoromethyl)cyclopropyl)phenyl)-4-methyl-1H-tetrazol-5(4H)-one(110 mg, 0.35 mmol),2-chloro-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)-4-pyrimidineaminehydrochloride (112 mg, 0.35 mmol) and para-toluenesulfonic acidmonohydrate (66 mg, 0.35 mmol) in IPA (7.5 mL) was heated to reflux andstirred for 7 days. After allowing to cool, 3-aminobenzoic acid (100 mg)added and the mixture stirred at reflux overnight. After cooling, themixture was concentrated under vacuum and the residue portioned betweenEtOAc (30 mL) and 1N NaOH (30 mL). The aqueous and organic layers werepartitioned and the organic layer was dried (MgSO₄), filtered and thesolvent removed under vacuum to leave a residue (LC/MS indicates this tobe product and unreacted aniline). The residue was triturated with Et₂Oand the emerging precipitate was filtered and the filter cake washedwith Et₂O to give the product (48 mg, 24%) as a solid. [Note: there isstill a lot of product in the filtrate].

¹H NMR (d₆-DMSO, 300 MHz): δ 8.56 (br. s, 1H), 7.92 (d, 1H), 7.84 (d,1H), 7.25-7.19 (m, 2H), 4.22 (m, 1H), 3.58 (s, 3H), 2.23 (m, 1H), 2.02(m, 1H), 1.57 (m, 2H), 1.26 (m, 2H), 1.14-1.07 (m, 2H), 0.97 (s, 12H).¹⁹F NMR (d₆-DMSO, 282 MHz): −65.6, −120.1, −165.8. m/z=568.7 (M+H)⁺

The above reaction was also undertaken starting with 106 mg of1-(2-bromo-4-fluoro-5-nitrophenyl)-4-methyl-1H-tetrazol-5(4H)-one togive the product (55 mg, 47%).

¹H NMR (CDCl₃, 300 MHz): δ 8.19 (dd, 1H), 7.22 (d, 1H), 3.74 (s, 3H),2.69-2.62 (m, 1H), 1.78-1.69 (m, 1H), 1.50-1.43 (m, 1H), 1.29-1.22 (m,1H). ¹⁹F NMR (CDCl₃, 282 MHz): −112.9 (dd, J=7.1, 7.1 Hz), −67.6 (d,J=6.2 Hz). m/z=389.2 (M+MeCN+H)⁺

Example 3 Preparation oftrans-4-fluoro-5-nitro-2-(2-(trifluoromethyl)cyclopropyl)-aniline

A mixture of 2-bromo-4-fluoro-5-nitroaniline (see (US 20110130415, whichis hereby incorporated by reference) (353 mg, 1.5 mmol),trans-2-(trifluoromethyl)cyclopropylboronic acid MIDA ester (477 mg, 1.8mmol), Pd(OAc)₂ (51 mg, 0.23 mmol), Cy₃P (126 mg, 0.45 mmol) and Cs₂CO₃(2.93 g, 9.0 mmol) in toluene (5 mL) and H₂O (1.5 mL) was de-gassed withN₂ for 15 minutes, then placed under a nitrogen atmosphere and heated toreflux for 3 hours. The temperature of the reaction mixture was reducedto 100° C. (block temperature) and the mixture stirred overnight. Aftercompletion of the reaction, the reaction mixture was cooled and EtOAc(100 mL) and H₂O (100 mL) were added. The reaction mixture was filteredthrough Celite and the filter cake washed with H₂O (50 mL) and EtOAc (50mL). The aqueous and organic layers of the filtrate were partitioned,and the aqueous layer was extracted with EtOAc (1×50 mL). The combinedorganic layers were washed with brine (1×50 mL), dried (MgSO₄), filteredand the solvent removed under vacuum to leave a crude residue. Theresidue was dry-loaded on to silica gel and purified by columnchromatography on silica gel using EtOAc/hexane (2:8 to 3:7) as eluentto give the product (214 mg, 54%).

¹H NMR (300 MHz, d₆-DMSO): δ 7.32 (dd, J=6.8, 2.3 Hz, 1H), 7.03 (dd,J=12.6, 2.0 Hz, 1H), 5.60 (br. s, 2H), 2.49-2.41 (m, 1H), 2.36-2.29 (m,1H), 1.42-1.35 (m, 1H), 1.16-1.11 (m, 1H). ¹⁹F NMR (282 MHz, d₆-DMSO): δ−135.7 (dd, J=6.9, 6.8 Hz), −64.8 (d, J=7.0 Hz). m/z=265.87 (M+H);m/z=263.00 (M−H)⁺.

Example 4 Preparation oftrans-3-(trifluoromethyl)cyclopropyl)-5-(pentafluorosulfur)aniline

In an open sealed tube, a stirred mixture of3-bromo-5-(pentafluorosulfur)aniline (JRD Fluorochemicals Ltd., UnitedKingdom) (75 mg, 0.25 mmol), palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the mixture placed undernitrogen, sealed and heated to 115° C. and stirred overnight. Afterallowing to cool, the reaction mixture was diluted with H₂O (15 mL) andEtOAc (20 mL), filtered through Celite and the filter cake washed withEtOAc (2×20 mL). The filtrate was partitioned and the aqueous layerextracted with EtOAc (2×15 mL). The combined organic extracts were dried(Na₂SO₄), filtered and concentrated under vacuum to leave a cruderesidue. The residue was purified by preparative thin-layerchromatography (4 prep TLC plates used) using EtOAc/hexane (1:4) aseluent to give the product (62.4 mg, 76%) as a solid.

¹H NMR (CDCl₃, 300 MHz): δ 6.91 (t, J=2.0 Hz, 1H), 6.85 (t, J=1.7 Hz,1H), 6.54 (s, 1H), 3.87 (br. s, 2H), 2.35-2.28 (m, 1H), 1.87-1.74 (m,1H), 1.42-1.35 (m, 1H), 1.21-1.14 (m, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ147.2, 141.3, 127.7 (q, J=270 Hz), 116.0, 114.2 (t, J=4.7 Hz), 111.2 (t,J=4.7 Hz), 23.5 (q, J=37.3 Hz), 19.9 (q, J=2.7 Hz), 11.1 (q, J=2.5 Hz).¹⁹F NMR (CDCl₃, 282 MHz): −66.9 (d, J=7.1 Hz), −114.2 (m), −137.4 (s),−138.0 (s). m/z=369.00 (M+MeCN+H)⁺. HRMS (EI): [M+MeCN+H]⁺ calc'd forC₁₀H₉F₈NS+MeCN m/z 369.0672. found 369.0624.

Example 5 Preparation oftrans-2-(2-(trifluoromethyl)cyclopropyl)naphthalene

In an open vial with pressure-release top, a stirred mixture of2-bromonaphthylene (Aldrich, St. Louis, Mo.) (52 mg, 0.25 mmol),palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, sealed and heated to 100° C. and stirred for 6 hours.After allowing to cool, the reaction mixture was diluted with H₂O (15mL) and EtOAc (20 mL), filtered through Celite and the filter cakewashed with EtOAc (2×20 mL). The filtrate was partitioned and theaqueous layer extracted with EtOAc (2×15 mL). The combined organicextracts were dried (Na₂SO₄), filtered and concentrated under vacuum toleave a crude residue. The residue was purified by preparativethin-layer chromatography (2 prep TLC plates used) using EtOAc/hexane(1:99) as eluent to give the product (38.1 mg, 65%) as a solid.

¹H NMR (CDCl₃, 300 MHz): δ 7.81-7.75 (m, 3H), 7.57 (s, 1H), 7.50-7.41(m, 2H), 7.21 (d, J=1.7 Hz, 1H), 2.56-2.49 (m, 1H), 1.97-1.84 (m, 1H),1.47-1.40 (m, 1H), 1.31-1.25 (m, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ 136.7,133.7, 132.7, 128.7, 128.1 (q, J=269 Hz), 128.0, 127.8, 126.7, 126.1,125.4, 124.5, 23.5 (q, J=36.6 Hz), 20.2 (q, J=2.6 Hz), 11.1 (q, J=2.6Hz). ¹⁹F NMR (CDCl₃, 282 MHz): −66.7 (d, J=7.1 Hz). m/z=no mass iondetected by either LC/MS or HRMS

Example 6 Preparation oftrans-2-(2-(trifluoromethyl)cyclopropyl)naphthalene

In an open vial with pressure-release top, a stirred mixture of2-chloronaphthylene (TCI America, Portland, Oreg.) (41 mg, 0.25 mmol),palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, sealed and heated to 100° C. and stirred for 6 hours.After allowing to cool, the reaction mixture was diluted with H₂O (15mL) and EtOAc (20 mL), filtered through Celite and the filter cakewashed with EtOAc (2×20 mL). The filtrate was partitioned and theaqueous layer extracted with EtOAc (2×15 mL). The combined organicextracts were dried (Na₂SO₄), filtered and concentrated under vacuum toleave a crude residue. The residue was purified by preparativethin-layer chromatography (2 prep TLC plates used) using EtOAc/hexane(1:99) as eluent to give the product (31.7 mg, 54%) as a solid.

Data identical to above in Example 5.

Example 7 Preparation oftrans-2-(2-(trifluoromethyl)cyclopropyl)naphthalene

In an open vial with pressure-release top, a stirred mixture of2-iodonaphthylene (Aldrich, St. Louis, Mo.) (64 mg, 0.25 mmol),palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, sealed and heated to 100° C. and stirred for 6 hours.After allowing to cool, the reaction mixture was diluted with H₂O (15mL) and EtOAc (20 mL), filtered through Celite and the filter cakewashed with EtOAc (2×20 mL). The filtrate was partitioned and theaqueous layer extracted with EtOAc (2×15 mL). The combined organicextracts were dried (Na₂SO₄), filtered and concentrated under vacuum toleave a crude residue. The residue was purified by preparativethin-layer chromatography (2 prep TLC plates used) using EtOAc/hexane(1:99) as eluent to give the product (46.2 mg, 78%) as a solid.

Data identical to above in Example 5.

Example 8 Preparation oftrans-2-(2-(trifluoromethyl)cyclopropyl)naphthalene

In an open vial with pressure-release top, a stirred mixture of2-naphthyltrifluoromethanesulfonate (Aldrich, St. Louis, Mo.) (69 mg,0.25 mmol), palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, sealed and heated to 100° C. and stirred for 6 hours.After allowing to cool, the reaction mixture was diluted with H₂O (15mL) and EtOAc (20 mL), filtered through Celite and the filter cakewashed with EtOAc (2×20 mL). The filtrate was partitioned and theaqueous layer extracted with EtOAc (2×15 mL). The combined organicextracts were dried (Na₂SO₄), filtered and concentrated under vacuum toleave a crude residue. The residue was purified by preparativethin-layer chromatography (2 prep TLC plates used) using EtOAc/hexane(1:99) as eluent to give the product (45.9 mg, 78%) as a solid.

Data identical to above in Example 5.

Example 9 Preparation oftrans-6-(2-(trifluoromethyl)cyclopropyl)-2,3-dihydro-1H-inden-1-one

In an open ChemGlass vial with pressure-release top, a stirred mixtureof 6-bromo-1-indanone (Aldrich, St. Louis, Mo.) (53 mg, 0.25 mmol),palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, sealed and heated to 100° C. and stirred overnight.After allowing to cool, the reaction mixture was diluted with H₂O (15mL) and EtOAc (20 mL), filtered through Celite and the filter cakewashed with EtOAc (2×20 mL). The filtrate was partitioned and theaqueous layer extracted with EtOAc (2×15 mL). The combined organicextracts were dried (Na₂SO₄), filtered and concentrated under vacuum toleave a crude residue. The residue was purified by preparativethin-layer chromatography (3 prep TLC plates used) using EtOAc/hexane(1:4) as eluent to give the product (53.8 mg, 90%) as an oil.

¹H NMR (CDCl₃, 300 MHz): δ 7.46 (s, 1H), 7.43 (m, 2H), 3.14-3.10 (m,2H), 2.73-2.68 (m, 2H), 2.45-2.38 (m, 1H), 1.87-1.76 (m, 1H), 1.45-1.38(m, 1H), 1.25-1.18 (m, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ 207.0, 154.1,139.0, 137.8, 134.2, 127.8 (q, J=271 Hz), 127.2, 121.0, 36.9, 25.8, 23.7(q, J=36.8 Hz), 19.5 (q, J=2.7 Hz), 11.1 (q, J=2.6 Hz). ¹⁹F NMR (CDCl₃,282 MHz): −66.9 (d, J=5.9 Hz). m/z=282.05 [M+MeCN+H]⁺

HRMS (EI): [M+MeCN+H]⁺ calc'd for C₁₃H₁₁F₃O+MeCN m/z 282.1106. found282.1100.

Example 10 Preparation of1-(diethoxymethyl)-3-(2-(trifluoromethyl)cyclopropyl)benzene

In an open ChemGlass vial with pressure-release top, a stirred mixtureof 3-bromobenzaldehyde diethylacetal (Aldrich, St. Louis, Mo.) (65 mg,0.25 mmol), palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, sealed and heated to 100° C. and stirred overnight.After allowing to cool, the reaction mixture was diluted with H₂O (15mL) and EtOAc (20 mL), filtered through Celite and the filter cakewashed with EtOAc (2×20 mL). The filtrate was partitioned and theaqueous layer extracted with EtOAc (2×15 mL). The combined organicextracts were dried (Na₂SO₄), filtered and concentrated under vacuum toleave a crude residue. The residue was purified by preparativethin-layer chromatography (3 prep TLC plates used) using EtOAc/hexane(1:4) as eluent to give the product (58.6 mg, 69%-yield adjusted forpurity) as an oil [note: desired product contaminated with anothercompound after prep TLC—approximately 85% pure by ¹H NMR and LC/MS].

¹H NMR (CDCl₃, 300 MHz): δ 7.34-7.24 (m, 3H), 7.08 (dt, J=7.1, 1.7 Hz,1H), 5.46 (s, 1H), 3.67-3.48 (m, 4H), 2.40-2.34 (m, 1H), 1.88-1.75 (m,1H), 1.40-1.31 (m, 1H), 1.24 (t, J=7.1 Hz, 6H), 1.20-1.14 (m, 1H). ¹⁹FNMR (CDCl₃, 282 MHz): −66.8 (d, J=6.8 Hz). m/z=no mass-ion by LC/MS orHRMS.

Example 11 Preparation oftrans-1-tert-butyl-4-(2-(trifluoromethyl)cyclopropyl)benzene

In an open ChemGlass vial with pressure-release top, a stirred mixtureof 4-tert-butylbromobenzene (Oakwood, West Columbia, S.C.) (53 mg, 0.25mmol), palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, sealed and heated to 100° C. and stirred overnight.After allowing to cool, the reaction mixture was diluted with H₂O (15mL) and EtOAc (20 mL), filtered through Celite and the filter cakewashed with EtOAc (2×20 mL). The filtrate was partitioned and theaqueous layer extracted with EtOAc (2×15 mL). The combined organicextracts were dried (Na₂SO₄), filtered and concentrated under vacuum toleave a crude residue. The residue was purified by preparativethin-layer chromatography (3 prep TLC plates used) using hexane aseluent to give the product (49.1 mg, 81%) as an oil.

¹H NMR (CDCl₃, 300 MHz): δ 7.36 (d, J=8.2 Hz, 2H), 7.07 (d, J=8.6 Hz,2H), 2.38-2.32 (m, 1H), 1.87-1.74 (m, 1H), 1.39-1.33 (m, 1H), 1.32 (s,9H), 1.20-1.11 (m, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ 150.1, 136.4, 128.1(q, J=268 Hz), 126.5, 125.9, 34.8, 31.7, 23.9 (q, J=36.8 Hz), 19.5 (q,J=2.7 Hz), 11.1 (q, J=2.6 Hz). ¹⁹F NMR (CDCl₃, 282 MHz): −66.7 (d, J=6.8Hz). m/z=no mass-ion by LC/MS or HRMS.

Example 12 Preparation oftrans-1-methoxy-4-(2-(trifluoromethyl)cyclopropyl)benzene

In an open ChemGlass vial with pressure-release top, a stirred mixtureof 3-bromoanisole (Aldrich, St. Louis, Mo.) (47 mg, 0.25 mmol),palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, sealed and heated to 100° C. and stirred overnight.After allowing to cool, the reaction mixture was diluted with H₂O (15mL) and EtOAc (20 mL), filtered through Celite and the filter cakewashed with EtOAc (2×20 mL). The filtrate was partitioned and theaqueous layer extracted with EtOAc (2×15 mL). The combined organicextracts were dried (Na₂SO₄), filtered and concentrated under vacuum toleave a crude residue. The residue was purified by preparativethin-layer chromatography (3 prep TLC plates used) using EtOAc/hexane(1:4) as eluent to give the product (20.4 mg, 24%-yield adjusted forpurity) as an oil (ca. 60% pure contaminated with starting material).

¹H NMR (CDCl₃, 300 MHz): δ 7.08-7.03 (m, 2H), 6.81-6.76 (m, 2H), 3.79(d, J=0.5 Hz, 3H), 2.35-2.28 (m, 1H), 1.76-1.66 (m, 1H), 1.35-1.26 (m,1H), 1.15-1.07 (m, 1H). ¹⁹F NMR (CDCl₃, 282 MHz): −66.7 (d, J=7.1 Hz).m/z=no mass-ion by LC/MS

Example 13 trans-tert-butyl 3-(2-(trifluoromethyl)cyclopropyl)benzoate

In an open ChemGlass vial with pressure-release top, a stirred mixtureof 3-bromobenzoic acid tert-butyl ester (Combi-Blocks, San Diego,Calif.) (mg, 0.25 mmol), palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, sealed and heated to 100° C. and stirred overnight.After allowing to cool, the reaction mixture was diluted with H₂O (15mL) and EtOAc (20 mL), filtered through Celite and the filter cakewashed with EtOAc (2×20 mL). The filtrate was partitioned and theaqueous layer extracted with EtOAc (2×15 mL). The combined organicextracts were dried (Na₂SO₄), filtered and concentrated under vacuum toleave a crude residue. The residue was purified by preparativethin-layer chromatography (3 prep TLC plates used) using EtOAc/hexane(1:4) as eluent to give the product (23.3 mg, 23%—yield adjusted forpurity) as an oil. [note: product contaminated withby-product—approximately 70% pure by ¹H NMR].

¹H NMR (CDCl₃, 300 MHz): δ 8.01-7.98 (m, 1H), 7.86-7.84 (m, 1H), 7.73(s, 1H), 7.44-7.38 (m, 1H), 2.43-2.37 (m, 1H), 1.91-1.78 (m, 1H), 1.60(s, 9H), 1.47-1.37 (m, 1H), 1.25-1.18 (m, 1H). ¹⁹F NMR (CDCl₃, 282 MHz):−66.8 (d, J=6.8 Hz). m/z=no mass-ion by LC/MS.

Example 14 Preparation oftrans-5-(2-(trifluoromethyl)cyclopropyl)pyrimidine

A stirred mixture of 5-bromopyrimidine (Aldrich, St. Louis, Mo.) (80 mg,0.5 mmol), palladium(II) acetate (11 mg, 0.05 mmol),tricyclohexylphosphine (28 mg, 0.1 mmol), K₂CO₃ (276 mg, 2.0 mmol) andtrans-2-(trifluoromethyl)cyclopropylboronic acid MIDA ester (146 mg,0.55 mmol) in toluene (3 mL) and H₂O (1 mL) was de-gassed with N₂ for 15minutes, then the reaction mixture placed under nitrogen, heated toreflux and stirred overnight. After allowing to cool, the reactionmixture was filtered through Celite and the filter cake washed withEtOAc (3×10 mL). The filtrate was concentrated under vacuum and theresidue purified by preparative thin-layer chromatography (4 prep TLCplates used) using EtOAc/hexane (1:1) as eluent to give the product (30mg, 32%) as a solid.

¹H NMR (CDCl₃, 300 MHz): δ 9.12 (s, 1H), 8.57 (s, 2H), 2.40-2.33 (m,1H), 1.98-1.87 (m, 1H), 1.57-150 (m, 1H), 1.32-1.25 (m, 1H). ¹³C NMR(CDCl₃, 75 MHz): δ 157.7, 155.7, 132.8, 127.4 (q, J=269 Hz), 23.1 (q,J=37.4 Hz), 15.3 (q, J=2.9 Hz), 10.6 (q, J=2.6 Hz). ¹⁹F NMR (CDCl₃, 282MHz): −67.2 (d, J=7.1 Hz) m/z=188.98 (M+H)⁺. HRMS (EI): [M+H]⁺ calc'dfor C₈H₇F₃N₂ m/z 189.0640. found 189.0659.

Also obtained from the preparative thin-layer chromatography plates wasan unidentified mixture of products (13 mg).

Example 15 Preparation oftrans-7-(2-(trifluoromethyl)cyclopropyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine

In an open sealed tube, a stirred mixture of7-bromo-3,4-dihydro-2-pyrido[3,2-b][1,4]oxazoline (Maybridge, UnitedKingdom) (108 mg, 0.5 mmol), palladium(II) acetate (11 mg, 0.05 mmol),tricyclohexylphosphine (28 mg, 0.1 mmol), K₂CO₃ (276 mg, 2.0 mmol) andtrans-2-(trifluoromethyl)cyclopropylboronic acid MIDA ester (159 mg, 0.6mmol) in toluene (3 mL) and H₂O (1 mL) was de-gassed with N₂ for 15minutes, then the reaction mixture placed under nitrogen, heated to 115°C. and stirred for 4 days. After allowing to cool, the reaction mixturewas filtered through Celite and the filter cake washed with EtOAc (3×20mL), H₂O (10 mL) and EtOAc (20 mL). The aqueous and organic layers ofthe filtrate were partitioned and the aqueous layer extracted with EtOAc(1×20 mL). The combined organic extracts were dried (Na₂SO₄), filteredand the solvent removed under vacuum to leave a crude residue. Theresidue was purified by preparative thin-layer chromatography (4 prepTLC plates used) using EtOAc as eluent to give the product (21 mg, 17%)as a solid.

¹H NMR (CDCl₃, 300 MHz): δ 7.54 (s, 1H), 6.70 (d, J=1.6 Hz, 1H), 4.99(br. s, 1H), 4.21 (dt, J=4.4, 0.7 Hz, 2H), 3.53 (t, J=4.4 Hz, 2H),2.26-2.19 (m, 1H), 1.74-1.61 (m, 1H), 1.33-1.26 (m, 1H), 1.10-1.03 (m,1H). ¹³C NMR (CDCl₃, 75 MHz): δ 146.6, 139.8, 138.8, 128.0 (q, J=269Hz), 125.4, 120.7, 65.0, 40.8, 22.7 (q, J=36.7 Hz), 17.0 (q, J=2.8 Hz),10.2 (q, J=2.2 Hz). ¹⁹F NMR (CDCl₃, 282 MHz): −66.8 (d, J=6.8 Hz).m/z=245.09 (M+H)⁺

HRMS (EI): [M+H]⁺ calc'd for C₁₁H₁₁F₃N₂O m/z 245.0902. found 245.0909.

Also obtained from the preparative thin-layer chromatography plates wasrecovered 7-bromo-3,4-dihydro-2-pyrido[3,2-b][1,4]oxazoline (18 mg, 17%)and reduced starting material, 3,4-dihydro-2-pyrido[3,2-b][1,4]oxazoline(9.4 mg, 14%). Note: the above reaction also was successfully undertakenusing the alternative ligands2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl, or2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl.

Example 16 Preparation oftrans-6-(-2-(trifluoromethyl)cyclopropyl)-[1,2,4]triazolo[1,5-a]pyridine

In an open sealed tube, a stirred mixture of6-bromo[1,2,4]triazolo[4,3-a]pyridine (Ark Pharm, Inc., Libertyville,Ill.) (50 mg, 0.25 mmol), palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (1.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, heated to 115° C. and stirred overnight. After allowingto cool, the reaction mixture was diluted with EtOAc (30 mL) and H₂O (30mL), then filtered through Celite and the filter cake washed with EtOAc(3×10 mL). The aqueous and organic layers of the filtrate werepartitioned and the aqueous extracted with EtOAc (2×15 mL). The combinedorganic extracts were dried (Na₂SO₄), filtered and the solventconcentrated under vacuum to leave a crude residue. The residue waspurified by preparative thin-layer chromatography (4 prep TLC platesused) using CH₂Cl₂/MeOH (95:5) as eluent to give the product (31.8 mg,56%) as a solid.

¹H NMR (CDCl₃, 300 MHz): δ 8.82 (s, 1H), 8.08 (s, 1H), 7.76 (d, J=9.5Hz, 1H), 7.09 (dd, J=9.5, 1.4 Hz, 1H), 2.43-2.36 (m, 1H), 1.95-1.82 (m,1H), 1.51-1.44 (m, 1H), 1.30-1.22 (m, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ149.1, 135.8, 127.5 (q, J=269 Hz), 126.1, 121.3, 116.7, 22.5 (q, J=37.3Hz), 17.1 (q, J=2.9 Hz), 9.9 (q, J=2.5 Hz). ¹⁹F NMR (CDCl₃, 282 MHz):−66.9 (d, J=6.2 Hz). m/z=228.01 (M+H)⁺. HRMS (EI): [M+H]⁺ calc'd forC₁₀H₈F₃N₃ m/z 228.0749. found 228.0721.

Example 17 Preparation oftrans-5-(2-(trifluoromethyl)cyclopropyl)benzo[d]thiazole

In an open sealed tube, a stirred mixture of 5-bromobenzothiazole(Combi-Blocks, Inc., San Diego, Calif.) (54 mg, 0.25 mmol),palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, sealed and heated to 115° C. and stirred overnight.After allowing to cool, the reaction mixture was diluted with H₂O (15mL) and EtOAc (20 mL), filtered through Celite and the filter cakewashed with EtOAc (2×20 mL). The filtrate was partitioned and theaqueous layer extracted with EtOAc (2×15 mL). The combined organicextracts were dried (Na₂SO₄), filtered and concentrated under vacuum toleave a crude residue. The residue was purified by preparativethin-layer chromatography (4 prep TLC plates used) using EtOAc/hexane(1:9) as eluent to give the product (43.7 mg, 72%) as an oil.

¹H NMR (CDCl₃, 300 MHz): δ 8.99 (s, 1H), 7.89-7.86 (m, 2H), 7.28-7.24(m, 1H), 2.57-2.50 (m, 1H), 1.95-1.82 (m, 1H), 1.49-1.42 (m, 1H),1.31-1.24 (m, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ 155.0, 154.0, 138.0,132.4, 127.9 (J=269 Hz), 125.2, 122.2, 121.4, 23.9 (q, J=36.8 Hz), 19.9(q, J=2.7 Hz), 11.4 (q, J=2.6 Hz). ¹⁹F NMR (CDCl₃, 282 MHz): −66.8 (d,J=6.8 Hz). m/z=243.98 (M+H)⁺. HRMS (EI): [M+H]⁺ calc'd for C₁₁H₈F₃NS m/z244.0408. found 244.0406.

Example 18 Preparation of trans4-(2-(trifluoromethyl)cyclopropyl)phthalazin-1(2H)-one

In an open, sealed tube a stirred mixture of 1-chloro-4-phthalazinone(Maybridge, United Kingdom) (45 mg, 0.25 mmol), palladium(II) acetate(5.5 mg, 0.025 mmol), 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl(23 mg, 0.05 mmol), K₂CO₃ (138 mg, 1.0 mmol) andtrans-2-(trifluoromethyl)cyclopropylboronic acid MIDA ester (99 mg, 0.38mmol) in toluene (2.5 mL) and H₂O (0.5 mL) was de-gassed with N₂ for 15minutes, then the reaction mixture placed under nitrogen, sealed andheated to 115° C. and stirred overnight. After allowing to cool, thereaction mixture was diluted with H₂O (15 mL) and EtOAc (20 mL), then 1NHCl was added until pH 6-7. The reaction mixture was filtered throughCelite and the filter cake washed with EtOAc (2×20 mL). The filtrate waspartitioned and the aqueous layer extracted with EtOAc (2×15 mL). Thecombined organic extracts were dried (Na₂SO₄), filtered and concentratedunder vacuum to leave a crude residue. The residue was purified bypreparative thin-layer chromatography (4 prep TLC plates used) usingEtOAc/hexane (1:1) as eluent to give a mixture of the product andstarting 1-chloro-4-phthalazinone (35 mg). The mixture was separated byhigh-performance liquid chromatography to give the product (20 mg, 31%)as a solid.

¹H NMR (d₆-DMSO, 300 MHz): δ 12.54 (br. s, 1H), 8.26 (d, J=7.9 Hz, 1H),8.17 (d, J=7.7 Hz, 1H), 8.00 (t, J=7.6 Hz, 1H), 7.86 (t, J=7.6 Hz, 1H),2.95-2.88 (m, 1H), 2.42-2.28 (m, 1H), 1.45-1.37 (m, 2H). ¹³C NMR(d₆-DMSO, 75 MHz): δ 160.3, 143.3, 134.6, 132.7, 131.5, 129.0 (q, J=270Hz), 128.3, 126.9, 125.7, 20.9 (q, J=36.0 Hz), 16.5 (q, J=2.8 Hz), 9.6(q, J=2.4 Hz). ¹⁹F NMR (d₆-DMSO, 282 MHz): −64.8 (d, J=7.6 Hz).m/z=255.02 (M+H)⁺; 253.05 (M−H)⁺. HRMS (EI): [M+H]⁺ calc'd for C₁₂H₉F₃NOm/z 255.0745. found 255.0744.

Example 19 Preparation oftrans-2-(2-(trifluoromethyl)cyclopropyl)thiazole

In an open, sealed tube a stirred mixture of 2-bromothiazole (Aldrich,St. Louis, Mo.) (41 mg, 0.25 mmol), palladium(II) acetate (5.5 mg, 0.025mmol), 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05mmol), K₂CO₃ (138 mg, 1.0 mmol) andtrans-2-(trifluoromethyl)cyclopropylboronic acid MIDA ester (99 mg, 0.38mmol) in toluene (2.5 mL) and H₂O (0.5 mL) was de-gassed with N₂ for 15minutes, then the reaction mixture placed under nitrogen, sealed andheated to 115° C. and stirred overnight. After allowing to cool, thereaction mixture was diluted with H₂O (15 mL) and EtOAc (20 mL),filtered through Celite and the filter cake washed with EtOAc (2×20 mL).The filtrate was partitioned and the aqueous layer extracted with EtOAc(2×15 mL). The combined organic extracts were dried (Na₂SO₄), filteredand concentrated under vacuum to leave a crude residue. The residue waspurified by preparative thin-layer chromatography (4 prep TLC platesused) using EtOAc/hexane (5:95) as eluent to give the product (23 mg,33%; sample contains an equivalent mole of EtOAc—yield adjusted forEtOAc content).

Note: the ¹H and ¹³C NMR contains ca. 1 mole equivalent of EtOAc—afterNMRs were obtained, the sample was concentrated and placed on a highvacuum. However, the sample disappeared, indicating the product may bevolatile.

¹H NMR (CDCl₃, 300 MHz): δ 7.65 (d, J=4.6 Hz, 1H), 7.19 (d, J=4.6 Hz,1H), 2.76-2.67 (m, 1H), 2.39-2.26 (m, 1H), 1.57-1.47 (m, 2H). ¹³C NMR(CDCl₃, 75 MHz): δ 171.5, 142.8, 127.3 (q, J=266 Hz), 118.3, 24.7 (q,J=36.8 Hz), 17.8 (q, J=2.7 Hz), 13.1 (q, J=2.8 Hz). ¹⁹F NMR (CDCl₃, 282MHz): −67.2 (d, J=5.9 Hz). m/z=234.99 (M+MeCN+H)⁺.

HRMS (EI): [M+H]⁺ calc'd for C₇H₆F₃NS m/z 194.0251. found 194.0251.

Example 20 Preparation oftrans-1-methyl-5-(2-(trifluoromethyl)cyclopropyl)-1H-indazole

In an open sealed tube, a stirred mixture of5-bromo-1-methyl-1H-indazole (Combi-Blocks, Inc., San Diego, Calif.) (53mg, 0.25 mmol), palladium(II) acetate (5.5 mg, 0.025 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (23 mg, 0.05 mmol),K₂CO₃ (138 mg, 1.0 mmol) and trans-2-(trifluoromethyl)cyclopropylboronicacid MIDA ester (99 mg, 0.38 mmol) in toluene (2.5 mL) and H₂O (0.5 mL)was de-gassed with N₂ for 15 minutes, then the reaction mixture placedunder nitrogen, sealed and heated to 115° C. and stirred overnight.After allowing to cool, the reaction mixture was diluted with H₂O (15mL) and EtOAc (20 mL), filtered through Celite and the filter cakewashed with EtOAc (2×20 mL). The filtrate was partitioned and theaqueous layer extracted with EtOAc (2×15 mL). The combined organicextracts were dried (Na₂SO₄), filtered and concentrated under vacuum toleave a crude residue. The residue was purified by preparativethin-layer chromatography (4 prep TLC plates used) using EtOAc/hexane(2:8) as eluent to give the product (20 mg, 33%) as a solid.

¹H NMR (d₆-DMSO, 300 MHz): δ 7.94 (d, J=0.8 Hz, 1H), 7.56-7.52 (m, 2H),7.23 (dd, J=8.7, 1.7 Hz, 1H), 4.00 (s, 3H), 2.51-2.46 (m, 1H), 2.29-2.17(m, 1H), 1.37-1.24 (m, 2H). ¹³C NMR (d₆-DMSO, 75 MHz): δ 139.7, 132.8,131.8, 129.1 (q, J=269 Hz), 126.1, 124.5, 118.2, 110.6, 36.3, 23.1 (q,J=35.6 Hz), 20.1 (q, J=2.7 Hz), 11.9 (q, J=2.5 Hz). ¹⁹F NMR (d₆-DMSO,282 MHz): −64.9 (d, J=7.6 Hz). m/z=241.05 (M+H)⁺. HRMS (EI): [M+H]⁺calc'd for C₁₂H₁₁F₃N₂ m/z 241.0953. found 241.0948.

Example 21 Structure of trans-2-(trifluoromethyl)cyclopropylboronic acidMIDA ester from x-ray crystallography studies

A clear colorless plate-like specimen of C₉H₁₁BF₃NO₄, approximatedimensions 0.05 mm×0.20 mm×0.20 mm, was used for the X-raycrystallographic analysis. The X-ray intensity data were measured.

The total exposure time was 61.81 hours. The frames were integrated withthe Bruker SAINT software package using a narrow-frame algorithm. Theintegration of the data using a monoclinic unit cell yielded a total of3721 reflections to a maximum θ angle of 67.14° (0.84 Å resolution), ofwhich 3721 were independent (average redundancy 1.000,completeness=91.9%, R_(sig)=4.97%) and 3221 (86.56%) were greater than2σ(F²). The final cell constants of a=21.215(2) Å, b=10.0689(9) Å,c=10.6637(9) Å, β=96.454(6)°, volume=2263.5(4) Å³, are based upon therefinement of the XYZ-centroids of 2081 reflections above 20 σ(I) with13.15°<2θ<132.5°. Data were corrected for absorption effects using themulti-scan method (SADABS). The ratio of minimum to maximum apparenttransmission was 0.747. The calculated minimum and maximum transmissioncoefficients (based on crystal size) are 0.7779 and 0.9368.

The structure was solved and refined using the Bruker SHELXTL SoftwarePackage, using the space group P 1 c 1, with Z=8 for the formula unit,C₉H₁₁BF₃NO₄. The final anisotropic full-matrix least-squares refinementon F² with 654 variables converged at R1=7.80%, for the observed dataand wR2=23.17% for all data. The goodness-of-fit was 1.057. The largestpeak in the final difference electron density synthesis was 0.557 e⁻/Å³and the largest hole was −0.515 e⁻/Å³ with an RMS deviation of 0.110e⁻/Å³. On the basis of the final model, the calculated density was 1.555g/cm³ and F(000), 1088 e⁻.

FIG. 1 shows the structure oftrans-2-(trifluoromethyl)cyclopropylboronic acid MIDA ester from X-raycrystallography studies.

While the present invention has been described with reference to thespecific embodiments thereof, it should be understood by those skilledin the art that various changes may be made and equivalents may besubstituted without departing from the true spirit and scope of theinvention. In addition, many modifications may be made to adapt aparticular situation, material, composition of matter, process, processstep or steps, to the objective, spirit and scope of the presentinvention. All such modifications are intended to be within the scope ofthe claims appended hereto.

1.-51. (canceled)
 52. A method of forming a compound of formula I:

wherein R¹ is selected from hydrogen, alkyl, substituted alkyl, alkenyl,substituted alkenyl, alkynyl, substituted alkynyl, aryl, and heteroaryl;and R^(2a), R^(2b), R^(2c), and R^(2d) are independently selected fromhydrogen, alkyl, substituted alkyl, halogen, hydroxyl, cyano, phosphate,alkoxy, substituted alkoxy, carboxyl, carboxyl ester, aryl, substitutedaryl, heteroaryl, substituted heteroaryl, heterocyclyl, substitutedheterocyclyl, alkenyl, substituted alkenyl, amino, substituted amino,acyl, acylamino, aminoacyl, alkoxycarbonylamino, thiol, alkylthiol,substituted thioalkoxy, and sulfonyl, wherein at least one of R^(2a),R^(2b), R^(2c), and R^(2d) is not hydrogen; comprising reacting acompound of formula 3a:

with a compound of formula 3b:


53. The method of claim 52, wherein R¹ is alkyl.
 54. The method of claim52, wherein one of R^(2a), R^(2b), R^(2c), and R^(2d) is substitutedalkyl and the others are hydrogen.
 55. The method of claim 52, whereinone of R^(2a), R^(2b), R^(2c), and R^(2d) is trifluoromethyl and theothers are hydrogen.
 56. The method of claim 55, wherein the compound offormula I has a trans stereochemistry with respect to the cyclopropylring.
 57. A method of forming a compound of formula 4c:

R^(2a), R^(2b), R^(2c), and R^(2d) are independently selected fromhydrogen, alkyl, substituted alkyl, halogen, hydroxyl, cyano, phosphate,alkoxy, substituted alkoxy, carboxyl, carboxyl ester, aryl, substitutedaryl, heteroaryl, substituted heteroaryl, heterocyclyl, substitutedheterocyclyl, alkenyl, substituted alkenyl, amino, substituted amino,acyl, acylamino, aminoacyl, alkoxycarbonylamino, thiol, alkylthiol,substituted thioalkoxy, and sulfonyl, wherein at least one of R^(2a),R^(2b), R^(2c), and R^(2d) is not hydrogen; comprising reacting acompound of formula 4a:

with a compound of formula 4b:


58. The method of claim 57, wherein one of R^(2a), R^(2b), R^(2c), andR^(2d) is substituted alkyl and the others are hydrogen.
 59. The methodof claim 57, wherein one of R^(2a), R^(2b), R^(2c), and R^(2d) istrifluoromethyl and the others are hydrogen.
 60. The method of claim 59,wherein the compound of formula 4c has a trans stereochemistry withrespect to the cyclopropyl ring.
 61. A method of forming a compound offormula 5c:

wherein R^(2a), R^(2b), R^(2c), and R^(2d) are independently selectedfrom hydrogen, alkyl, substituted alkyl, halogen, hydroxyl, cyano,phosphate, alkoxy, substituted alkoxy, carboxyl, carboxyl ester, aryl,substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl,substituted heterocyclyl, alkenyl, substituted alkenyl, amino,substituted amino, acyl, acylamino, aminoacyl, alkoxycarbonylamino,thiol, alkylthiol, substituted thioalkoxy, and sulfonyl, wherein atleast one of R^(2a), R^(2b), R^(2c), and R^(2d) is not hydrogen;comprising reacting a compound of formula 5a:

wherein each R is independently an alkyl or taken together with theatoms to which they are attached are a cyclic pinacolato boronate ester,with a compound of formula 5b:

wherein R¹ is selected from H, Li, Na and K.
 62. The method of claim 61,wherein each R is independently selected from methyl, n-propyl,isopropyl and n-butyl.
 63. The method of claim 61, wherein the Rsubstituents taken together with the atoms to which they are attachedare a cyclic pinacolato boronate ester.
 64. The method of claim 61,wherein R¹ is Na.
 65. The method of claim 61, wherein one of R^(2a),R^(2b), R^(2c), and R^(2d) is substituted alkyl and the others arehydrogen.
 66. The method of claim 61, wherein one of R^(2a), R^(2b),R^(2c), and R^(2d) is trifluoromethyl and the others are hydrogen. 67.The method of claim 66, wherein the compound of formula 5c has a transstereochemistry with respect to the cyclopropyl ring.
 68. The method ofclaim 61, wherein the reacting occurs in a polar aprotic solvent. 69.The method of claim 68, wherein the polar aprotic solvent is DMSO orDMF.
 70. The method of claim 61, further comprising heating the polaraprotic solvent.